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SUMMARY
Chronic hypoxia (CH) induces pulmonary hypertension and pulmonary vascular 
remodelling. Accompanying this, the pulmonary vascular bed becomes hyper-reactive 
to vasoconstrictors, which was demonstrated in the isolated perfused rat lung. 
Agonists such as phenylephrine (PHE), KC1, angiotensin II (Ang II), noradrenaline 
(NA) and U46619 all produced enhanced responses, suggesting a common 
mechanism was responsible.
As in CH lungs endothelin (ET) synthesis is increased, its role in pulmonary vascular 
hyper-reactivity was studied. ET-1 sensitized pulmonary vasculature to PHE and Ang 
II in the normoxic lungs via ETA and ETB receptors. PKC and the Na+/H* exchanger 
are not involved in this sensitization. However ET-1 did not potentiate vasoconstrictor 
responses to KC1. Furthermore in CH lungs ET receptor antagonists and an ET 
converting enzyme inhibitor did not affect the potentiated vasoconstrictor responses 
seen in CH lungs. Thus a role for ET-1 to pulmonary vascular hyper-reactivity during 
CH was not found.
Time-dependent study of vasoconstrictor responses and pulmonary vascular 
remodeling in CH showed that the increase in responses to the vasoconstrictors Ang II 
and KC1 during hypoxia (3 weeks) and recovery (3 weeks) parallels pulmonary 
vascular remodelling. However the decline of PHE-induced vasoconstrictor responses 
during recovery is faster than regression of pulmonary vascular hypertrophy. These 
differences suggest that another mechanism apart from an increase in the number of 
pulmonary smooth muscle cells must be involved in the potentiated responses to PHE.
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1.1 Hypoxic pulmonary hypertension
Alveolar hypoxia (hypoxia) is defined as a decrease of the partial pressure of oxygen 
(PO2) in the environment. Exposure to hypoxia provokes a series of modifications in the 
human body, including the pulmonary circulation. Pulmonary vasculature is very 
sensitive to changes of alveolar PO2 . An interesting phenomenon is that the pulmonary 
circulation reacts to hypoxia by vasoconstriction, but the systemic vessels usually dilate 
in response to hypoxia (Brij and Peacock, 1998). Hypoxic pulmonary vasoconstriction 
(HPV) is important in keeping an optimal ventilation/perfusion ratio and preventing 
systemic hypoxaemia. However, in chronic hypoxia (CH), HPV is persistent and 
followed by the muscularization of the pulmonary vessels, which results in the 
development of pulmonary hypertension.
The pulmonary circulation is a capacitive and low resistance system. Small changes in 
pressure induce large changes in arterial diameter. There is little active vasomotor tone, 
arterial pressure being around 15 mmHg in normal condition in humans. In pulmonary 
hypertension, systolic pulmonary artery pressure may exceed 25 mmHg (Bishop et a l , 
1995; Egermayer et al., 1999).
Clinically, most pulmonary hypertension occurs in people living at high altitude or with 
chronic obstructive pulmonary diseases due to hypoxia. Primary pulmonary hypertension 
is a condition associated with progressive elevation in the pulmonary pressure, for which 
no underlying cause can be found. In newborn babies, a dramatic transition of the
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pulmonary circulation from a high resistance state in utero to a low-resistance state 
occurs within minutes after birth. If the pulmonary vascular resistance fails to decrease, 
this will lead to pulmonary hypertension, a condition known as persistent pulmonary 
hypertension of the newborn. Perinatal hypoxia is thought to be the reason for the 
persistant pulmonary hypertension of the newborn (Abman, 1999). Anorexigens such as 
fenfluramine can induce pulmonary hypertension, which may be due to increased 5- 
hydroxytryptamine (5-HT) levels in the lungs (Valodia & Syce, 2000). Other reasons for 
pulmonary hypertension are congenital systemic to pulmonary shunts, pulmonary 
embolism and sarcoidosis (Galie & Torbicki, 2001). Exposure to hypoxia is a common 
model for experimental study of pulmonary hypertension. Monocrotaline-induced 
pulmonary hypertension is another useful animal model for study of pulmonary 
hypertension (Ito et a l , 1988; Wanstall & O’Donnell, 1990). Monocrotaline, a 
pyrrolizidine plant alkaloid, is metabolized in the liver into an active pyrrole form, which 
causes pulmonary endothelial damage leading to pulmonary edema, protein leakage and 
cellular filtration and then gradually induces pulmonary hypertension (Mathew & Altura, 
1990; Wilson et al, 1992). Although the initial factors may differ widely between 
different forms of pulmonary hypertension, chronic pulmonary hypertension commonly 
results in decreased pulmonary vascular compliance, progressive elevation in pulmonary 
artery pressure, increase in pulmonary resistance, right ventricular hypertrophy and 
ultimately heart failure (Giaid et a l, 1993; Salvi, 1999).
3
1.2 HPV
HPV, first described by Von Euler and Liljestrand in 1946, is an important physiological 
process involved in the matching of regional pulmonary blood flow to regional 
ventilation. Alveolar hypoxia diverts blood flow from poorly ventilated alveoli to the 
better-ventilated regions, thereby optimizing ventilation/perfusion ratio matching and 
maintaining an adequate systemic PO2 . In the foetus, this HPV serves to increase 
pulmonary vascular resistance and divert blood flow from the pulmonary circulation into 
the systemic circulation through the ductus arteriosus. The foetal pulmonary circulation 
therefore only receives up to 10% of the cardiac output (Sansoucie & Cavaliere, 1997). 
After birth, HPV is an important negative feedback mechanism required for ventilation- 
perfusion matching. HPV has been demonstrated in a variety of species, e.g. rat, rabbit, 
cat, pig, calf, sheep and human (reviewed by Wadsworth, 1994).
The pulmonary artery tree is a complex system due to regional differences in structure 
and functions (Kemp et al., 1997). There are 15 orders of arteries between the main 
pulmonary artery and the capillaries in human lungs, which are divided into three 
descending segments, namely, elastic arteries, muscular arteries and arterioles (Sasaki et 
al., 1995; Huang et al., 1996). The main pulmonary artery and primary branches of 
pulmonary arteries are elastic arteries, which are essentially similar to large systemic 
conductive arteries, e.g. aorta. These pulmonary arteries have well-developed internal and 
external elastic laminae and a less distinct medial layer than that of systemic arteries 
(reviewed by Maclean et al., 2000). Distal to the elastic pulmonary arteries, pulmonary
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arteries taper to the muscular arteries, defined by diameters from 100 pm to 1mm. 
Pulmonary arteries <100 pm in rats tend to have no media or only a scattering of smooth 
muscle cells, and are called arterioles (Sasaki et al., 1995; MacLean, 1999a; Salvi, 1999). 
The last order of the pulmonary artery tree is 20 pm in diameter in humans and 13 pm in 
diameter in rats (Huang et al., 1996). HPV occurs at different levels of the pulmonary 
artery tree, in both the large and small arteries (Yuan et al., 1990). However, the small 
muscular pulmonary arteries and arterioles of the pulmonary artery tree are thought to be 
the major site of HPV when considering the increase of pulmonary resistance (MacLean, 
1999a; Salvi, 1999). The study of isolated feline pulmonary smooth muscle cells has 
shown the importance of the small pulmonary artery for HPV because the smooth muscle 
cells from small pulmonary arteries exhibited significant contraction during hypoxia, 
whereas the cells from large pulmonary arteries did not contract much (Madden et al., 
1992). Using an X-ray TV system, the internal diameters of the feline pulmonary arteries 
(100 - 600 pm) were monitored. The percentage reduction of the internal diameter during 
acute hypoxia was greater in pulmonary arteries of 200 -  300 pm internal diameters than 
in large pulmonary arteries up to 600 pm (Shirai et al., 1986).
There are two main stages to HPV demonstrated in rat pulmonary arterial rings: a rapid 
transient constriction stage, called phase 1; and a slow, long-sustained stage, called phase 
2. Phase 1 occurs independently of the pulmonary endothelium and is thought to result 
from membrane depolarization of the pulmonary smooth muscle cells; phase 2 is 
endothelium-dependent, requiring the release of vasoconstrictors from the endothelial 
cells (Bennie et al., 1991; Robertson et al., 1995). In contrast to pulmonary vasculature,
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responses to hypoxia in systemic arteries (e.g. aorta, bronchial artery, mesenteric artery, 
coronary artery and femoral artery) are different from the pulmonary artery (Leach et al., 
2000; Liu et a l, 2001), a complete relaxation occurs after a small initial increase in 
tension. Therefore, an intrinsic mechanism for HPV exists specifically in pulmonary 
vasculature.
The exposure to hypoxia causes potassium channel (K+ channel) inhibition, inducing 
membrane depolarization in the pulmonary arterial smooth muscle cells, but not in the 
vascular smooth muscle cells from systemic arteries, e.g. renal artery and mesenteric 
artery (Karamsetty et a l, 1995). That is because there are different K+ channel 
distributions in pulmonary and systemic arterial smooth muscle cells (Weir & Archer, 
1995; Brij & Peacock, 1998), In the systemic arteries, ATP sensitive K+ (K atp)  channels 
are opened during hypoxia, thereby hyperpolarizing the membrane and inhibiting calcium 
(Ca2+) influx (Brij & Peacock, 1998). Voltage-dependent K+ (Kv) channels are 
responsible for the membrane depolarization in pulmonary arterial smooth muscle cells 
during hypoxia (Barman, 1998). It has been demonstrated that mRNA expression of Kv 
channel a-subunits was decreased in pulmonary smooth muscle cells during hypoxia but 
not in mesenteric artery smooth muscle cells (Platoshyn et a l, 2001). Three sub-types of 
Kv channel a-subunit, namely K V2.i , K vi .5 and K V3.i are responsible for the membrane 
depolarization in pulmonary smooth muscle cells during hypoxia (Archer et a l, 1998).
Membrane depolarization brings the membrane potential to a level where L-type Ca2+ 
channels can be opened, leading to increased Ca2+ influx into the vascular smooth muscle
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cells (Post et a l, 1992; Evans et al, 1998; Doi et al, 2000b). Increase of intracellular 
Ca concentration ([Ca ];) in pulmonary vascular smooth muscle cells is essential in the 
development and maintenance of pulmonary hypertension by mediating pulmonary 
vasoconstriction and stimulating pulmonary vascular smooth muscle proliferation 
(Platoshyn et a l, 2001). The Ca2+ channel agonist BAY K8644 potentiated HPV and
t y t
nifedipine, a Ca channel blocker inhibited it in both resting pulmonary rings and those 
pre-stimulated with either phenylephrine (PHE) or angiotensin II (Ang II), which 
suggests that HPV involves Ca2+ entry through voltage-dependent Ca2+ channels 
(Rodman et a l, 1989). Ca2+ influx is the major source of depolarization-induced increase 
of [Ca2+]i rather than Ca2+ release from the internal store, even though there is evidence
2"bthat Ca release is also involved in the membrane depoplarization of smooth muscle 
cells (Erne & Hermsmeyer, 1991; Barman, 1998).
It is universally accepted that hypoxia induces K+ channel inhibition on the membrane of 
pulmonary vascular smooth muscle cells. However, it is uncertain how the smooth 
muscle cells sense and transmit the changes of PO2 to the K+ channels on the cell’s 
membrane. It is presumed that an O2 sensor exists in pulmonary smooth muscle cells. Kv 
channels could be the O2 sensor by themselves, which directly detect the change of O2 
tension (Coppock et a l, 2001). Another candidate might be the electron transport chain in 
mitochondria, because inhibitors of the proximal region of the electron transport chain 
(rotenone, myxothaizol and diphenyleneiodonium) abolished HPV in isolated perfused 
lungs and cultured pulmonary smooth muscle cells, without affecting the pulmonary 
vasoconstrictor responses to U46619 (Archer et a l, 1993).
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Membrane depolarization could be an initial reaction to hypoxia in pulmonary 
vasculature. If hypoxia is prolonged, a persistent elevation in pulmonary arterial pressure 
appears which is not immediately or totally correctable upon improvement in oxygen 
concentration and cannot be explained solely by membrane depolarization. Locally- 
released vascular mediators are important in the regulation of pulmonary vascular tone in 
CH (Raj et al., 1992). Among such mediators endothelin-1 (ET-1), as a potent 
vasoconstrictor, is strongly implicated in hypoxic pulmonary hypertension (Michael & 
Markewitz, 1996; MacLean, 1999a). The role of mediators in the regulation of 
pulmonary vascular tone will be discussed later.
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1.3 Pulmonary vascular remodelling CH
HPV is the initial event in the pulmonary circulation during hypoxia, followed by 
pulmonary vascular remodelling; both of them contribute to pulmonary hypertension 
(MacLean, 1999a). Hypertrophy and hyperplasia of the pulmonary arterial smooth 
muscle cells and an increase of matrix in muscular pulmonary arteries are known as 
pulmonary vascular remodelling (Rabinovitch et a l , 1979; Kourembanas & Bemfield, 
1994). Smooth muscle cells also extend into distal, previously partly- or non-muscular 
arterioles (Hislop & Reid, 1976). The elastic laminae also increase in pulmonary arteries 
during CH (Liu, 1997). Hypoxia also increases intimal thickness by causing hypertrophy 
and hyperplasia in both the endothelial and subendothelial layers (Durmowicz & 
Stenmark, 1999). The increases of wall thickness in CH were found in all size ranges of 
pulmonary artery (Hislop & Reid, 1976). The cellular and structural changes observed in 
pulmonary hypertension vary significantly, depending on the duration and degree of 
hypoxic exposure (Durmowicz & Stenmark, 1999). The increase of the vascular wall 
thickness observed in small pulmonary arteries in mice happens as early as after 2 days of 
hypoxia (Quinlan et a l , 2000). Right ventricular hypertrophy, another parameter of 
pulmonary vascular remodelling, appeared after 5 days of exposure to hypoxia (Hislop & 
Reid, 1976). Vascular remodelling also occurs in pulmonary veins during hypoxia. A 
significant but smaller degree of medial thickness was observed in small pulmonary veins 
compared to the arteries (Takahashi et a l , 2001).
Pulmonary vascular remodelling is reversible and the regression process depends on the
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duration of exposure to hypoxia. 10 days hypoxia (10% O2) significantly increased the 
pulmonary arterial wall thickness compared to the controls. In recovery rats, which were 
returned to normoxic conditions, the pulmonary arterial wall thickness decreased 
continuously and reached normal levels after 30 days (Liu, 1997). Rats under hypoxia 
(11% O2) for 4 weeks displayed a significant increase in medial thickness of the 
pulmonary artery. After 4 weeks recovery, the rats still exhibited the same increase in 
pulmonary medial thickness as hypoxic rats (Dingemans & Wagenvoort 1978). In other 
words, pulmonary vascular remodelling from 4 week- hypoxic rats needs more than 4 
weeks to recover to the normoxic level.
ET-1, Ang II, 5-HT have all been demonstrated to stimulate proliferation of pulmonary 
smooth muscle cells (Jeffery & Wanstall, 1999; Eddahibi et a l , 2000; MacLean et al.,
2000). Therefore, these mediators might contribute to pulmonary vascular remodelling 
during CH.
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1.4 Pulmonary vascular hyper-reactivity during CH
CH induces not only pulmonary vasoconstriction and pulmonary remodelling but also 
pulmonary vascular hyper-reactivity. The earliest report of pulmonary vascular hyper­
reactivity during CH is to Ang II, prostaglandin F2tt and noradrenaline (NA) by 
McMurtry (1978), using isolated perfused rat lungs. Later, Emery et al., (1981) reported 
that Ang II- and ATP-induced vasoconstrictor responses were potentiated in perfused 
lungs of CH rats. The threshold dose-responses to Ang II and ATP in control and CH rats 
were not changed, only at the higher doses were vasoconstrictor responses significantly 
enhanced in CH lungs. Until now, pulmonary vascular hyper-reactivity during CH has 
not been thoroughly investigated. Although it is generally accepted that vasoconstrictors 
produce higher responses in lungs from CH animals, vasoconstrictor responses in 
pulmonary artery rings are varied. For example, in CH rats ET-1-induced contractile 
responses were potentiated in the pulmonary resistance arteries, but reduced in main 
pulmonary arteries (McCulloch et al., 1998; Lai et al., 1999a).
The mechanism of pulmonary vascular hyper-reactivity is not clear. It could be due to 1) 
pulmonary vascular remodelling; 2) increase in receptor linked second messenger 
processes; 3) receptor ‘cross-talk’ amplifying effects of one agonist; 4) sensitisation of 
contractile elements to Ca ; 5) membrane depolarization. The possible contributions of 
each of these mechanisms to vascular hyper-reactivity are discussed below.
Pulmonary vasculature shows vasoconstriction during the early stage of hypoxic
11
pulmonary hypertension, and this is gradually supplanted by progressive structural 
changes, so called ‘muscularization’ (Meyrick & Perkett, 1989). The pulmonary vascular 
hyper-reactivity is thought to be due to this pulmonary vascular remodelling. Because 
this new muscle encroaches on the vascular lumen and makes it narrower, a given degree 
of muscle shortening which reduces the vessel circumference, will cause a larger 
percentage reduction in radius and a higher increase in vascular pressure (Emery et al., 
1981).
Certainly hyper-reactivity appears confined to pulmonary vessels as in ovine uterine 
artery, vasoconstrictor responses to NA were attenuated in CH (Hu et al., 1999). This was 
associated with a decrease of IP3 binding affinity to its receptors was found during CH. In 
pulmonary artery, an increase in receptor-linked second messenger processes during CH 
appears to contribute to vascular hyper-reactivity
MacLean et al. (1994a) have reported that sumatriptan (a 5-HTio/iB-receptor agonist) 
fails to induce contraction of bovine pulmonary arteries in the absence of tone. However, 
under pre-contraction with U46619, sumatriptan is a potent vasoconstrictor. This might 
be another possibility to explain pulmonary vascular hyper-reacitivity during CH in 
which pulmonary hypertension unmasks receptor-mediated vasoconstriction.
Agonist (e.g. NA and Ang II) -induced vasoconstrictor responses in certain vessels can be 
potentiated in the presence of a threshold concentration of a second agonist (e.g. ET-1) 
(Yang et al., 1990; Nakayama et a l , 1991; Wong-Dusting et al., 1991). This could be due
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to crosstalk between agonists acting via different G protein-coupled receptors, which 
amplify the signals (MacLean, 1999b). Or, the second agonist, e.g. ET-1 could increase 
the sensitivity of the contractile apparatus to Ca in the vascular smooth muscle cells 
(Ohanian et al., 1997; Evans et al. 1999). In the mesenteric artery of normotensive rats, 
ET-1 potentiated NA-induced vasoconstrictor responses and this potentiation effect was 
prevented by BQ788, a selective ETb receptor antagonist. Furthermore, in mesenteric 
arteries of hypertensive rats, vasoconstrictor responses to NA were potentiated compared 
to normotensive rats, and this potentiation effect was also attenuated by BQ788 (Kita et 
al., 1998). Thus in these situations where vascular production of ET-1 is known to 
increase (Schifffin, 1999), vascular hyper-reactivity may result.
The vasoconstrictor responses to 5-HT were also potentiated in isolated perfused canine 
lungs during acute hypoxia induced in canine lung lobes ventilated by 95% N2 gas 
mixture. In these acute experiments cromakalim, a K a t p  channel opener, attenuated 
hypoxia-induced potentiation of vasoconstrictor responses to 5-HT (Barman, 1998). It is 
reported that hypoxia depolarises the membrane potenatial via K+ channel (Archer et al.,
1998). The membrane depolarisation brings the membrane potential closer to the 
threshold for activation of L-type Ca2+ channels (Yuan et al., 1990; Evans et al., 1998).
• • o j .Vasoconstrictors can then induce extracellular Ca influx more easily during CH. 
Therefore it is possible that K+ channel inhibition plays a key role in pulmonary vascular 
hyper-reactivity during CH.
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1.5 Innervation of pulmonary vasculature and hypoxic pulmonary hypertension
The pulmonary vessels are innervated by sympathetic, parasympathetic (vagal) and 
nonadrenergic, noncholinergic nerves (El-Bermani, 1978). The density of sympathetic 
nerve fibers is extensively distributed around extrapulmonary arteries; the sympathetic 
innervation in the intrapulmonary arteries varies between species (Zorychta & 
Richardson, 1992; Bames & Liu, 1995). For example, sympathetic nerves are rich in 
human intrapulmonary arteries, but absent in rat intrapulmonary arteries (reviewed by 
Bames and Liu, 1995). The stimulation of sympathetic nerves of the pulmonary 
circulation increases pulmonary vascular resistance and pulmonary arterial pressure, 
which can be blocked by an a-adrenoceptor antagonist and abolished by chemical 
sympathectomy using 6-hydroxydopamine (Liu & Bames, 1994). The stimulation of 
parasympathetic nerves induces pulmonary vasodilation via muscarinic receptors on 
pulmonary vascular endothelium leading to NO release (Liu & Bames, 1994).
In the periphery, catecholamines, NA and adrenaline (Adr) are stored and released from 
two primary sites. Post-ganglionic sympathetic neurons are the major source of NA, 
whereas Adr is predominantly released along with NA into the blood stream from the 
adrenal medulla (O’Rourke & Vanhoutte, 1992). a 2-Adrenoceptors and p2-adrenoceptors 
located on sympathetic nerve endings modulate the release of NA from neurons. The 
activation of pre-junctional P2-adrenoceptors and a 2-adrenoceptors cause the increase and 
inhibition of NA release from the sympathetic nerve system, respectively (Vanhoutte et 
a l , 1981).
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NA and Adr can activate a-adrenoceptors (ai- and a 2-subtypes) inducing 
vasoconstriction and p-adrenoceptors (Pi-, p2- and p3-subtypes) inducing vasodilation in 
pulmonary vasculature (O'Rourke & Vanhoutte, 1992; Salvi, 1999). However, ai- 
adrenoceptors are the primary receptors, through which sympathetic nerves act in the 
pulmonary circulation (Bames & Liu, 1995). The ai-adreneceptors that are present in the 
small- and medium-sized pulmonary arteries mediate not only smooth muscle contraction 
but also proliferation and growth in humans (Salvi, 1999).
Sympathetic nerves may play a role in the maintenance of basal pulmonary vascular tone; 
however the pulmonary circulation receives less influence from parasympathetic 
innervation (Fishman, 1976; Bames & Liu, 1995). Much evidence shows that hypoxia 
apparently stimulates the sympathetic nervous system, including local synthesis, storage 
or release of catecholamines (Fishman, 1976; Heistad & Abboud, 1980). The 
chemoreceptors are also involved in the regulation of pulmonary vascular tone (Bamford 
et al., 1999; Prabhakar, 2000). The carotid body chemoreceptors which are located at the 
bifurcation of the common carotid artery are sensitive to oxygen tension by its type I cells 
(Brij & Peacock, 1998). Hypoxia stimulates type I cells to release the transmitter 
dopamine, which activates the afferent fibers of the carotid sinus nerve and activates the 
sympathetic nervous system. This results in vasoconstriction in muscle, redistribution of 
blood flow, increase of cardiac output, pulmonary vasoconstriction and hyperventilation 
(Lopez-Lopez et a l , 1989; Sugito et al., 1998).
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Sympathetic motor innervation is not necessary for the pulmonary pressor responses to 
hypoxia (Von Euler & Liljestrand, 1946; Reeves & Rubin, 1998). This conclusion is 
based on the fact that HPV has been demonstrated in various experimental models in vivo 
and in vitro. It is observed in pulmonary artery rings and in single pulmonary artery 
smooth muscle cells (Bennie et al., 1991; Madden et al., 1992; Weir & Archer, 1995; Liu 
et al., 2001). Also, the isolated lung preparation in which hypoxia can produce HPV is 
thought to be devoid of sympathetic connections (Fishman, 1976). However, this does not 
exclude a modulatory role for circulating catecholamines in hypoxic pulmonary 
hypertension. Prolonged exposure to hypoxia increases the levels of circulating NA and 
Adr (reviewed by Rostrup, 1998). This, coupled with the fact that hypoxia up-regulates 
al-adrenoreceptor density and down-regulates p-adrenoreceptor density in pulmonary 
arteries, would shift the balance further in favour of vasoconstriction and proliferative 
responses (Xie et al., 1991).
The pulmonary circulation is also an important site for clearance of circulating 
catecholamines in various species, including human, rat, rabbit, and dog lungs, mainly by 
uptake and metabolism in endothelial cells of the lung microvasculature (reviewed by 
Bakhle and Vane, 1974). There are two distinct mechanisms involved in catecholamine 
uptake, Uptakei and Uptake2 , corresponding to neuronal and extra-neuronal uptake, 
respectively. They have different kinetic properties as well as different substrates and 
inhibitor specificities. Uptakei is a high-affinity system with a relatively low maximum 
rate of uptake, whereas Uptake2 has low affinity for NA, but a much higher maximum 
rate (Iversen et al., 1971; Bakhle & Vane, 1974). The substrate specificity is also
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different for Uptakei and Uptake; Uptakei is relatively selective for NA, whereas 
Uptake2 also accumulates Adr and isoprenaline. After uptake, catecholamines are 
metabolised by monoamine oxidase and catechol-O-methyl transferase.
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1.6 Mediators involved in hypoxic pulmonary hypertension
It is presumed that a balance between the effects of endogenous vasodilators and 
vasoconstrictors regulates pulmonary vascular tone (MacLean, 1999a). Hypoxic 
pulmonary hypertension could result from either an increase of vasoconstrictor activity, 
e.g. ET-1, catecholamines, Ang II, 5-HT and thromboxane A2 (TxA.2), or a decrease of 
vasodilator, e.g. nitric oxide (NO), prostacyclin (PGI2) influences.
1.6.1 ET-1
ET-1 is a 21-amino acid peptide, which was first isolated from the supernatant fraction of 
cultured endothelial cells and found to have potent vasoactive properties by Yanagisawa 
et al. (1988). Endothelins (ETs) represent a family of structurally-related peptides, which 
have three ET isoforms (ET-1, ET-2 and ET-3). Human ET-1 is derived from a 212- 
amino acid precursor, prepro-endothelin, via a 38-amino acid intermediate, big ET-1. An 
endothelin-converting enzyme cuts big ET-1 to mature ET-1. Conversion to ET-1 
amplifies big ET-1 activity at least 100-fold (Hisaki et al., 1994). Obviously, the 
conversion of big ET-1 to ET-1 is a crucial step in the formation of the biologically active 
peptide. Many factors like hypoxia, thrombin, transforming growth factor beta and shear 
stress can induce ET production (Kourembanas et al., 1991; Wort et al., 2001). 
Phosphoramidon, a metalloproteinase inhibitor, markedly suppresses the conversion 
process of big ET-1 into the mature form (Hisaki et a l, 1994; Xu et al., 1994).
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Two types of ET receptors have been cloned to date, named as ETa and ETb receptors. 
The two classes of ET receptors are distinct in their ligand binding affinity and 
distribution in tissues. ETa and ETb receptors co-exist on the pulmonary vascular smooth 
muscle (Lai et al., 1996). ETa receptors have stronger affinity for ET-1; the activation of 
ETa receptors mediates smooth muscle contraction and cell proliferation (Wort et al., 
2001). ETb receptors have equal affinity towards all three isoforms of ET; the activation 
of ETb receptors causes vasoconstriction through the ETb2 sub-type and vasodilatation 
through the ETbi sub-type in the pulmonary circulation. ETb2 receptors are located on the 
pulmonary vascular smooth muscle cells. ETbi receptors, which mediate vasodilation by 
releasing vasodilators PGI2 and NO, are located on the pulmonary endothelial cells, 
(MacLean et a l, 1994b; Lai et a l, 1996). Lower concentrations of ETb receptor agonist 
elicit pulmonary vasodilation via ETbi receptors, whereas higher concentrations cause 
pulmonary vasoconstriction via ETb2 receptors. There are regional differences in the 
distribution of ET receptors within pulmonary vasculature. In extrapulmonary artery 
rings, ET-1 induces contractile responses via ETa receptors, whereas in intrapulmonary 
resistance arteries, ET-1 induces vasoconstriction mainly via ETB receptors (LaDouceur 
et al., 1993; MacLean et al., 1994b). In the whole lung, ET-1 operates mainly through the 
ETa receptors in the pulmonary vasculature. BQ-123, a selective ETa receptor antagonist 
attenuated the ET-1-induced vasoconstriction responses in isolated perfused rat lungs, 
whereas BQ788, a selective ETb receptor antagonist potentiated the vasoconstriction 
responses to ET-1 (Uhlig & Featherstone, 1997). The lung is also a major site for the 
clearance of ET-1 and ETB receptors contribute to the clearance of ET-1 (Dupuis et al., 
1996).
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ETs are likely to contribute to the pathogenesis of hypoxic pulmonary hypertension 
because of their ability to cause vasoconstriction and act as co-mitogens for vascular 
smooth muscle and pulmonary arterial fibroblasts (reviewed by Michael & Markewitz, 
1996). It has been shown that ET-1 concentration was elevated in the cultured endothelial 
cells exposed to hypoxia (Kourembanas et al., 1991). The plasma concentration of ET-1 
was elevated in rats with hypoxic pulmonary hypertension and in patients with 
pulmonary hypertension (Stewart et al., 1991; Yoshibayashi et a l, 1991). Furthermore 
ET converting enzyme activity is up-regulated in CH lungs (Li et a l, 1999; Lai et al,
2000). Much evidence has shown that ET-1 contributes to hypoxic pulmonary 
hypertension. BQ123 abolished HPV in porcine distal pulmonary arteries (Liu et al,
2001). Exposure to hypoxia increased the number of ETa receptors in the media of 
pulmonary resistance arteries (Jones & Morice, 1998). BQ-123 completely prevented the 
development of pulmonary artery hypertension and vascular remodelling in rats during 
CH (Chen et a l, 1993; DiCarlo et al, 1995). Bosentan, a combined ETa and ETb 
receptor antagonist, can protect rats against the development of pulmonary hypertension 
and right ventricular hypertrophy during CH (Eddahibi et a l, 1995). Therefore, ET-1 
might be a very important mediator for hypoxic pulmonary hypertension.
1.6.2 Ang II
Renin is released into the circulation from the kidney and converts angiotensinogen into 
angiotensin I in the plasma. Angiotensin I is converted by angiotensin converting enzyme
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into Ang II, mainly in the endothelium of pulmonary vasculature (Ng & Vane, 1967; Ito 
et al., 1988). Ang II effects are mediated via ATi and AT2 receptors. ATi are widely 
distributed throughout adult tissues, whereas AT2 are abundantly expressed throughout 
fetal tissues but decrease dramatically and rapidly after birth (Csikos et al., 1998).
Ang II is a potent agonist that causes contraction of vascular smooth muscle via the 
activation of ATi receptors (Brailoiu et a l, 1999; Kotani et al., 1999). Ang II is also a 
mitogenic factor, which induces proliferation of lung fibroblasts and vascular smooth 
muscle cells demonstrated by in vitro studies (Marshall et al., 2000). This mitogenic 
effect of Ang II is related to the stimulation of transforming growth factor p (Koibuchi et 
al., 1993; Siegert et a l, 1999). In addition, Ang II can stimulate collagen production in 
vascular smooth muscle cells, demonstrated in human arterial smooth muscle cells (Ford 
etal., 1999).
It has been shown that angiotensin converting enzyme activity is enhanced in the small 
muscular pulmonary arteries during CH (Morrell et a l, 1995a). Furthermore, angiotensin 
converting enzyme inhibitors, for example perindopril, captopril or quinapril can reduce 
the pulmonary wall thickness in CH rats (Morrell et a l, 1995a ; Jeffery & Wanstall,
1999). Supporting evidence comes from experiments showing that less pulmonary 
vascular remodelling appeared in angiotensin converting enzyme-deficient mice 
compared to wild-type mice during CH (Suylen et a l, 2001). Thus, Ang II may 
contribute to pulmonary vascular remodelling during hypoxia and ATi receptors are 
responsible for the effect of endogenous Ang II in the pulmonary vascular remodelling
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induced by hypoxia (Morrell et al., 1995b).
1.6.3 5-HT
5-HT is produced mainly in the enterochromaffin cells of the intestine, and is also 
released from pulmonary neuroendocrine cells and neuroepethelial bodies distributed 
throughout the airway (MacLean et al., 2000). Circulating 5-HT is stored in the platelets; 
so free 5-HT in plasma is extremely low. 5-HT is mainly taken up by the lung and 
inactivated by the pulmonary endothelial cells (Vane, 1969).
5-HT has vasoconstrictor and mitogenic effects in the pulmonary circulation (Eddahibi et 
al., 2 0 0 0 ). 5-HT receptor sub-types, 5HTid/ib and 5 -HT2A are involved in vasoconstrictor 
responses in pulmonary arteries of humans and rats (Cortijo et al., 1997; Shaw et al.,
2 0 0 0 ).
One important finding linking 5-HT and pulmonary hypertension is that patients taking 
anorexigens (e.g. fenfluramine) can develop pulmonary hypertension. Such drugs 
increase 5-HT release from the platelets; inhibit 5-HT uptake and monoamine oxidase 
activity that metabolizes 5-HT (MacLean, 1999a). Fawn-hooded rats also demonstrate the 
relationship between 5-HT and pulmonary hypertension. Pulmonary hypertension 
develops in fawn-hooded rats, which is thought to be due to 5-HT platelet storage 
deficiency (Gonzalez et al., 1998). When knock-out of the 5-HT transporter gene was 
undertaken, the mice developed less pulmonary hypertension and pulmonary vascular
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remodelling during CH compared to the controls (Eddahibi et al., 2000). Therefore, 5-HT 
is also implicated in hypoxic pulmonary hypertension.
1.6.4 TxA2
The formation of TxA2 from prostaglandin H2 is catalyzed by TxA2 synthase. TxA2 has 
been shown to possess a variety of biological effects, the most important effects of which 
are platelet aggregation and constriction of vascular smooth muscle (Raj et al., 1992; 
Bauer et al., 1999). TxA2 can induce vasoconstriction in pulmonary arteries. And also it 
has been demonstrated that TxA2 is present in the pulmonary vascular smooth muscle 
cells in rat intrapulmonary arteries (Ermert et al., 2000). Increased production of TxA2 
has been found in patients with primary pulmonary hypertension or chronic obstructive 
pulmonary disease by measuring the metabolite of TxA2 in urine (Christman et al., 1992; 
Davi et al., 1997). However, the role of TxA2 in hypoxic pulmonary hypertension needs 
to be extensively investigated.
1.6.5 Vasodilators and hypoxic pulmonary hypertension
During hypoxia, the increase of pulmonary vascular resistance could be due to a decrease 
of vasodilator influence. As a potent vasodilator, NO could contribute to the regulation of 
pulmonary vascular tone. However, most studies have shown that hypoxia increases NO 
production, even though some groups have shown that hypoxia inhibits NO synthesis in 
the pulmonary artery (Johns et al., 1989; Fike et a l , 1998; Berkenbosch et al., 2000;
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Quinlan et al., 2000). NO release was enhanced in the pulmonary circulation during acute 
hypoxia because N-monomethyl-L-arginine (L-NMMA), an inhibitor of NO synthase 
(NOS), increased HPV in in vivo and in vitro studies (Robertson et a l , 1990; Liu et al., 
1991; Sprague et al., 1992; Liu et al., 2001). Similar to acute hypoxia, during CH, L- 
NMMA and L-NAME also enhanced pulmonary arterial pressure in the isolated lungs of 
rats (Barer et al., 1993). CH induced up-regulation of the endothelial isoform of NOS 
(eNOS) in the endothelium of both large and small pulmonary arteries (Xue et al., 1994; 
Hampl et al., 1995; Le Cras et al., 1996; Tyler et al., 1999). Northern blot and 
immunohistochemical analyses also showed that the inducible isoform of NOS (iNOS) 
was enhanced in the vascular smooth muscle of large and small pulmonary arteries from 
CH rats (Xue & Johns, 1996). Furthermore, immunohistochemistry has demonstrated that 
the expression of soluble guanylyl cyclase, the primary receptor for NO, is increased in 
the smooth muscle cells of small pulmonary arteries and arterioles in hypoxic rat lungs 
(Li et al., 1999). Much severer pulmonary hypertension and pulmonary remodelling was 
seen in eNOS-knockout mice during CH than normal or eNOS-knockout mice in 
normoxia (Steudel et al., 1998; Fagan et al., 1999). Thus, a decrease in activity of the NO 
system is not the cause of hypoxic pulmonary hypertension during hypoxia. In fact the 
increases reported may serve to counterbalance the increase of pulmonary 
vasoconstriction induced by hypoxic stress.
PGL is another vasodilator, which is released from the pulmonary endothelial cells 
(Tuder et a l, 1999). During acute hypoxia, the cyclo-oxygenase inhibitor indomethacin 
which blocks the initial step in the formation of prostaglandins (Ermert et al., 1998) had
24
no effect on HPV induced in porcine distal pulmonary arteries (Liu et a l , 2001). The 
expression of PGI2 synthase in the pulmonary endothelium detected by 
immunohistochemistry analysis was decreased in the small and medium-sized pulmonary 
arteries from patients with primary pulmonary hypertension compared to normal 
pulmonary arteries (Tuder et al., 1999). Similarly, the production of PGI2 detected in the 
endothelium was decreased in the conductive and resistance pulmonary artery rings after 
CH exposure (Badesch et al., 1989). Also, a recent study has shown that pulmonary 
hypertension, pulmonary vascular remodelling and right ventricular hypertrophy after CH 
were developed more severely in PGI2 receptor-knockout mice compared to wild-type 
mice (Hoshikawa et al., 2001). It seems that a deficit of PGI2 production in the 
pulmonary endothelium during CH could be one factor contributing to hypoxic 
pulmonary hypertension.
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1.7 Signalling pathways in vascular smooth muscle contraction
Vasoconstrictors such as Ang n, ET-1 and a-adrenoceptor agonists bind to their specific 
receptors on vascular smooth muscle cells and induce vessel contraction. Although the 
receptors are different, they are all guanine nucleotide-binding protein (G protein)- 
coupled receptors. After agonists bind to G protein-coupled receptors, this binding 
hydrolyses phosphatidylinositol 4,5-bisphosphate by a phosphoinositide-specific 
phospholipase to generate two second messengers, inositol 1,4,5-triphosphate (IP3) and 
1,2-diacyl-sn-gylcerol (DAG) (Karaki, 1989; Hamada et al., 1997; Bauer et al., 1999). 
DAG can activate PKC, which has multiple functions in smooth muscle cells.
IP3 enters the cytoplasmic compartment whereby it has an agonist effect at specific IP3 
receptors located on sarcoplasmic reticulum (SR) in the smooth muscle cells. The 
activation of these IP3 receptors causes release of Ca from the intracellular stores. Ca 
released from the HVsensitive stores has both positive and negative feedback on its own 
release through altering the affinity of the receptor. The emptying of Ca2+ from IP3- 
sensitive Ca2+ stores has been proposed to promote Ca2+ influx through voltage-gated 
Ca2+ channels, thereby sustaining contraction (Gelband & Gelband, 1997). So, both Ca2+ 
release and Ca2+ influx are dependent on the formation of IP3 (Hamada et al., 1997; Hu et 
al., 1999). However, Ca2+ influx induced by membrane depolarization is the major source 
of [Ca2+]i increase induced by agonists (reviewed by McFadzean & Gibson, 2002).
Not all Ca2+ stores in the SR are mediated by IP3 receptors, another intracellular Ca2+-
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94-release channel is IP3 receptor-insensitive but sensitive to Ca and caffeine and can be 
inhibited by ryanodine, the so-called 'ryanodine receptor' (Ito et al., 1986; Sorrentino &
9+Reggiam, 1999). Ryanodine receptors mainly exist in skeletal and cardiac muscles. Ca 
acts on the ryanodine receptors on the SR, inducing Ca2+ release, known as Ca2+-induced 
Ca2+ release (CICR) (Itoh et a l , 1992; Maxwell et a l, 1998). So, membrane 
depolarization of vascular smooth muscle cells, induced by vasoconstrictors or high K+, 
opens L-type Ca2+ channels on the membrane leading to Ca2+ influx (Karaki et al., 1997); 
Ca2+ influx triggers an explosive release of stored Ca2+ from the SR (Neylon et al., 1995). 
However, there is no evidence showing that Ca2+ influx is able to activate Ca2+ release 
via IP3 receptors.
Following receptor activation induced by agonists on the membrane of the smooth
• 9+muscle cells, increased free Ca in the cells is returned to resting levels by uptake into 
SR via Ca2+-ATPase and removal from the cells via Na+-Ca2+ exchangers on the plasma 
membrane. Thapsigargin, a Ca2+-ATPase inhibitor blocks Ca2+-ATPase on the SR and 
thus can deplete the Ca2+ store in SR (Maxwell et al., 1998; Ivery et a l, 1999; Shimoda 
et al., 2000). Mitochondria are also involved in Ca2+ mobilization in vascular smooth 
muscle cells (Drummond & Tuft, 1999; Lagaud et a l, 1999; Doi et al., 2000a).
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1.8 The mechanism of vascular smooth muscle contraction sliding theory
The contractile apparatus of vascular smooth muscle includes thick and thin filaments, 
mainly comprising myosins and actins, respectively (Chien, 1990). Vascular myosin is 
composed of two heavy chains and two sets of light chain units (regulatory and alkali 
light chains) (Hathaway et al., 1991). The ‘heads’ (cross-bridges) of myosins, which are 
bundled together into thick filaments, undergo a cycle of high- and low-affinity binding 
to actins, energized by ATP hydrolysis (Walker et al., 1994).
A change of [Ca2+]j is the main mechanism which initiates vascular smooth muscle 
contraction and relaxation. The resultant increase in [Ca ]* mediated by vasoconstrictors 
enhances the binding of Ca2+ to calmodulin (CaM). A Ca2+-CaM complex activates 
myosin light chain kinase to phosphorylate the regulatory myosin light chain. This simple 
phosphorylation reaction triggers cycling of myosin cross-bridges along actin filaments, 
resulting in the sliding of the thick filaments and the thin filaments past each other and 
smooth muscle contraction. Following a reduction in [Ca ]i the regulatory myosin light 
chain is dephosphorylated, resulting in smooth muscle relaxation (Karaki et al., 1997).
Obviously regulatory myosin light chain phosphorylation is the pivotal factor that 
determines the extent of smooth muscle contraction. A balance between the activity of 
the Ca2+-dependent myosin light chain kinase and the Ca2+-independent myosin light 
chain phosphatase determines the extent of phosphorylation of myosin light chain. 
Myosin light chain kinase phosphorylates regulatory myosin light chain whereas myosin
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phosphatase catalyzes dephosphorylation of regulatory myosin light chain (Walsh, 1991). 
In other words, a decrease of the activity of myosin light chain phosphatase can enhance 
regulatory myosin light chain phosphorylation and induce smooth muscle contraction.
Differing from cardiac and skeletal muscles, vascular smooth muscle often remains in a 
contracted state for a long period while regulatory myosin light chain phosphorylation
9+and [Ca ]i decrease. This mechanical state of tension maintenance with slowly cycling of 
cross-bridges has been called the ‘Latch State’ (Hai & Murphy, 1989). [Ca2+]j during the 
latch state is much lower than in the early stage of smooth muscle contraction although 
Ca is necessary for maintenance of the latch state. This latch state could be due to 
slowing of cross-bridge detachment (Hathaway et al., 1991). However, there are no 
specific reports that changes of the latch state accounted with pulmonary vascular hyper­
reactivity during CH.
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1.9 The role of Ca2+ sensitization in vascular smooth muscle contraction
Not only does [Ca2+]i play an important role in determining contractions of vascular 
smooth muscle, but also Ca sensitization of smooth muscle myofilaments provides a 
key determinant of contractile force (Karaki, 1989). Ca2+ sensitization can be defined as 
the degree of vasoconstrictor response elicited above that expected for a given [Ca2+]*. 
So, myosin light chains get phosphorylated through a Ca2+ independent pathway, which 
induces smooth muscle cell contraction.
The existence of Ca2+ sensitization was demonstrated in experiments using permeabilized 
vessels. Agonists can increase force of contraction in permeabilized smooth muscle in 
which the [Ca2+]i is clamped with Ca2+ chelators and intracellular stores are depleted 
(Nishimura et al., 1992; Evans et al., 1999).
Inhibition of myosin light chain phosphatase could be a major mechanism of Ca2+ 
sensitization (Feng et al., 1999; Robertson et al., 2000; Fukata et al., 2001). Rho, which 
activates Rho-kinase and as a result, suppresses myosin light chain phosphatase activity, 
is demonstrated to be involved in agonist-induced Ca2+ sensitization in smooth muscle 
cells (Fukata, et al., 2001).
PKC might be also involved in Ca2+ sensitization in smooth muscle cells. In aortic rings, 
NA-induced contraction was potentiated by ET-1 in the absence of changes in stimulated
2“FCa entry, and staurosporine and calphostin, PKC inhibitors, prevented the potentiation
30
effect of ET-1 (Henrion & Laher, 1993). It is thought that PKC sensitizes smooth muscle 
cells via inhibiting myosin light chain phosphatase (Nishimura et al., 1989; Weissman et 
a l , 1999).
It has been demonstrated that tyrosine kinase plays a role in Ca sensitization m the 
mesenteric artery, but not in the pulmonary artery as Tyrphostin A23, a selective tyrosine 
kinase inhibitor, inhibited ET-1-induced vasoconstriction in permeabilized mesenteric 
arteries but not in permeabilized pulmonary arteries (Ohanian, et al., 1997; Evans, et al. 
1999).
Intracellular pH (pHi) is another important determinant for Ca2+ sensitization in vascular 
smooth muscle. pHi can vary due to changes of extracellular pH or the action of agonists
4^*and changes in pHi may affect [Ca ]j or affect the affinity of CaM with Ca (Smith et 
al., 1998). Intracellular alkalinization causes increases of [Ca2+]i and increases of 
pulmonary arterial pressure, as demonstrated in isolated ferret lungs. Furthermore, 
maintaining intracellular alkalinization causes a further increase of pulmonary arterial 
pressure without any change of [Ca2+]j (Farrukh et al., 1996).
The Na+/H+ exchanger and Na+/HC03" exchanger play a crucial role in the regulation of 
pHi as demonstrated in cultured guinea pig or ferret pulmonary arterial smooth muscle 
cells (Quinn et al., 1991; Farrukh et al., 1996). The Na+/H+ exchanger extrudes protons 
from the smooth muscle cells. So, inhibition of the Na+/H+ exchanger decreases pHi 
(Farrukh et al., 1996). Agonist activation of vascular smooth muscle (e.g. ET-1) may
involve increases in the activity of the Na+/H+ and the Na+/HC03' transporters and result 
in intracellular alkalinization and indirectly increase Ca sensitization (Wang et al, 
2000).
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1.10 Aims of this study
Pulmonary vascular hyper-reactivity during CH has not been investigated extensively and 
its mechanism is unknown. Previous studies have shown that ET-1 is involved in HPV 
and pulmonary vascular remodelling during CH because of its ability to cause 
vasoconstriction and act as co-mitogens for vascular smooth muscle and pulmonary 
arterial fibroblasts (reviewed by Michael & Markewitz, 1996). ET-1 can also sensitize the 
myofilaments to Ca2+ in pulmonary vascular smooth muscle cells (Evans et al., 1999). 
Therefore, ET-1 might play a role in the pulmonary vascular hyper-reactivity during CH. 
Emery et al. (1981) think that the potentiation of vasoconstrictor responses may be due to 
the pulmonary arterial remodelling. Because this new muscle encroaches on the vascular 
lumen and makes it narrower, a given degree of muscle shortening, which reduces the 
vessel circumference, will cause a larger percentage reduction in radius and a higher 
increase in vascular pressure. The relationship of pulmonary arterial muscularization and 
pulmonary vasoconstrictor responses during CH is under investigation to assess the role 
of pulmonary vascular remodelling in the pulmonary vascular hyper-reactivity.
Hence, the aims of this study are:
1) To investigate the effect of CH on the vasoconstrictor responses to agonists in isolated 
perfused rat lungs and pulmonary artery rings.
2) To determine whether endogenous ET-1 production mediates pulmonary vascular 
hyper-reactivity in the isolated perfused lungs from CH rats.
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3) To investigate the effects of ET-1 on vasoconstrictor responses to other agonists in 
normoxic isolated perfused lungs and the signalling pathways involved.
4) To determine the relationship between pulmonary vascular remodelling and pulmonary 
vascular hyper-reactivity during CH.
5) To determine whether effects of CH on catecholamine uptake can account for 






2.1 Hypoxic animal model
For CH animals, male Wistar rats (240 - 260g) were maintained in a chamber of 10% O2  
(v/v) for 3 weeks. The chamber was kept at room temperature (22 - 23°C) and suitable 
humidity (50 - 70%) in a re-circulating normobaric environment (Lai et al., 1999a). The 
re-circulating air was passed through a silica gel column to remove water vapour, while 
CO2 was absorbed through a soda lime column. Oxygen tension was continuously 
monitored using a Servomex 1440C gas analyzer (Lai et al., 1999a). Nitrogen was 
pumped into the chamber when O2 tension was more than 10.5%; and air was pumped 
into the chamber when O2 tension was less than 9.5%. The animals were used for 
experiment within 1 hour of removal from the chamber. For recovery studies, rats were 
transferred to room air after 3 weeks in the hypoxic chamber and utilized up to 3 weeks 
later. As indices of hypoxic pulmonary hypertension, haematocrit and ratio of right 
ventricular weight/total heart weight were measured. Only the free wall of the right 
ventricle, not including septum was weighed as right ventricular weight.
2.2 Isolated perfused lung preparation
Male Wistar rats were terminally anaesthetised with pentobarbital sodium (lOOmg/kg) 
intraperitoneally and heparinized (500IU) via the tail vein. The lungs were isolated after 
the pulmonary artery was cannulated via the right ventricle and the trachea was 
cannulated. The right and left ventricles were cut off to allow free efflux of fluid. The 
isolated lungs were perfused with Krebs’ solution from the cannula in the pulmonary
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artery, aerated by 20% O2 / 75% N2 / 5% C02, pH 7.3. The perfusion flow was fixed at 
5ml/min, 37 °C .The lungs were ventilated with room air, at 28 strokes/min. Pulmonary 
perfusion pressure (PPP) and pulmonary inflation pressure (PIP) were recorded through 
pressure transducers, which connected to the pulmonary artery cannula and the tracheal 
cannula, respectively. The effluent perfusate passed through left atrium and was not 
recirculated. Lungs were suspended from an isometric transducer for recording changes 
of lung weight (Figure 2.1, part A) (Lai et al., 1994).
Lungs were equilibrated for 15 min before adding drugs. Agonists were bolus-injected or 
infused into the pulmonary artery. Antagonists were infused for 15 min before injection 
of agonists.
For the study of ET-1 sensitization, ET-1 was infused for 30 min in normoxic lungs 
before bolus-injections of PHE, Ang II and KC1. For antagonist-treated groups, 
antagonists were infused during the last 15 min of ET-1 infusion.
In a series of experiments, the isolated lungs were perfused with low oxygen, 10% 0 2 / 
85% N2 / 5% C 02, pH at 6.56.
2.3 Rat stomach strip preparation for bioassay
For study of catecholamine metabolism in the lung, a rat stomach strip (RSS) was 
prepared from the fundus of rat stomach (Armitage and Vane, 1964), cut along the
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Part A Lung weight
Part B Isotonic transducer
Figure 2.1: Schematic illustration of isolated perfused lung and rat stomach strip preparation
Part A: Isolated perfused lung preparation. The lung was suspended and connected to an isometric 
transducer recording changes o f lung weight. Trachea and pulmonary artery were cannulated and 
connected to pressure transducers, recording PPP and PIP respectively.
Part B: RSS preparation. Infusions of NA or Adr were over the RSS tissue (OT) directly or through the 
lung (TL). The changes o f length o f the RSS were recorded via an isotonic transducer.
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4 min
| 10 nM j | 20 nM | | 20 nM |
OT TL OT
Figure 2.2: A typical experimental trace showing removal of NA in the isolated perfused 
lung.
The relaxation of the rat stomach strip was induced by NA, which was infused over the tissue 
directly (OT) or infused through the lung (TL). The rat stomach strip was pre-contracted with 
5-HT.
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longitude, about 3 - 4 cm long and 1.5- 2mm wide. The RSS was set up in an organ bath 
and superfused with Krebs’ solution at 5ml/min and 34°C. The upper end of the tissue 
was attached to an isotonic lever to record the change of tension. The load on the lever 
was 1 g.
5-HT (1 .5 -3  pM) was infused over the stomach strip for pre-contraction (Armitage & 
Vane, 1964). The stomach strip relaxed when NA (5 nM - 20 nM) or Adr (1 nM - 15 nM) 
was infused (5 min) through the lung or over the RSS tissue directly. The removal of 
catecholamines by lungs was determined by bracketing the RSS responses to 
catecholamines superfused over the RSS directly and through the lungs (Figure 2.1, part 
B and Figure 2.2) (Alabaster & Bakhle, 1973).
2.4 Isolated aortic ring preparation
Aortic rings (3 mm long) were dissected gently from thoracic aortae in normoxic or CH 
rats. The vessels were set up in 10ml organ baths with Krebs’ solution, bubbled with 95% 
0 2 /5 % CO2 at 37 °C. The aortic rings were equilibrated for 1 hour before starting 
experiments. Resting tension was set at lg and contraction of rings was recorded via an 
isometric transducer. Cumulative concentration-responses to PHE were recorded by a 
Maclab system.
2.5 Isolated perfused mesenteric bed
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The superior mesenteric artery was cannulated via the aorta and the colic artery was tied 
off. The mesenteric vascular bed was separated from the intestine and aorta and perfused 
with Krebs’ solution aerated by 95% 0 2 /5 % CO2 , pH 7.3. The perfusion flow was 
5ml/min, 37°C. Mesenteric perfusion pressure was recorded via a pressure transducer. All 
preparations were allowed to equilibrate for 15 min before drug administration.
2.6 Histologic analysis of pulmonary vasculature
Rats were anaesthetised with pentobarbital sodium (lOOmg/kg i.p.) and heparinized 
(500IU i.v.). The pulmonary artery was cannulated via the right ventricle. The heart was 
cut off to allow free efflux of perfusate. The isolated lungs were perfused with Krebs’ 
solution from the cannula in the pulmonary artery at a constant flow rate (5ml/min) for 5 
min, 37°C, then changed from Krebs’ solution to formol saline (0.4%) and perfused with 
formal saline for 5 min. The lungs (n = 5 rats / each group) were immersed in formol 
saline for at least 1 week. Three different lobes from the right lungs were embedded in 
paraffin separately. Transverse slices (4pm thickness) of lung tissue were taken from the 
middle of each lobe and stained with haematoxylin and eosin.
Sections were viewed under a microscope (JVC, KY-F55BF, Japan) with a computer 
analysis system (ZEISS, KS300). Measurements were made of external arterial diameter 
and medial thickness at 100 ~ 400 magnification. Pulmonary arteries were identified by 
accompanying airway and pulmonary veins (Figure 2.3). Histological changes were 
quantified as described by Hislop and Reid (1976). Vessel diameter was defined as the
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Figure 2.3: Representative micrograph showing the location of pulmonary artery
Pulmonary artery (PA) was identified by accompanying airway and pulmonary vein (PV), 
xlOO magnification.
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Figure 2.4: Measurement of pulmonary artery under microscope
Pulmonary vascular diameter (Xi and X2) and wall thickness (a,b,c,d) were identified by external 
elastic laminae (EEL) and internal elastic laminae (IEL), x400 magnification.
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distance between two diametrically opposed external elastic laminae (Figure 2.4); two 
measurements were made: one along the line corresponding to the longest distance and 
another one along the line perpendicular to it, and these two values were averaged to get 
mean arterial diameter. Medial wall thickness was defined and measured as the distance 
between the internal and the external elastic laminae; four measurements were made: one 
in each of the four quadrants defined by the perpendicular lines. The percentage wall 
thickness is calculated from the formula (Hislop & Reid, 1976):
Wall thickness (%) = 2 x Medial wall thickness x 100/ Diameter
All pulmonary arteries distinguished under the microscope were measured only if they 
were entire ones; around 60 vessels were measured from each rat.
2.7 Isolated pulmonary artery ring
2.7.1 Procedure of setting up
Male Wistar rats (200-250g) were killed by cervical dislocation. The heart and lung en 
bloc was removed and placed in Krebs’ solution. Pulmonary arteries were always 
obtained from the upper left lobe to avoid variation. The left pulmonary arteries (ID: 
1059 ± 95pm, n = 7) and the fourth order branches (ID: 234 ± 20pm, n = 7) of pulmonary 
arteries were dissected in Krebs’ solution under a dissection microscope. The bronchiole 
was the guide for tracing the pulmonary arteries because the bronchiole always overlaps
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on the top of the pulmonary artery from the ventral side of the lobe. Isolated pulmonary 
arteries were cleared of connective tissue and cut into 2mm lengths. The vessels were 
mounted in a dual Mulvany-Halpem myograph using two tungsten wires (25 pm 
diameter, Goodfellow Co. UK). One tungsten wire was attached to a micrometer, the 
other one attached to an isometric transducer (Grass Instruments Company, USA). The 
vessels were incubated in Krebs’ solution bubbled with 2 0 %0 2 /5 %C0 2 / 7 5 %N2 at 37°C, 
and stretched from zero to lmN and equilibrated for 1 hour.
2.7.2 Normalization of pulmonary artery on myograph
Following an equilibration, the passive length-tension relationship of the vessel was 
determined, called normalization (Mulvany & Halpem, 1977; Teng & Barer, 1995).
A) Internal circumference (IC):
IC (pm) = (Xi -Xo)x2  + (2 + II )xD
Xo (pm) is the micrometer reading when the two wires on the myograph just touch each 
other and bring the tension to zero. Xi (pm) is the micrometer reading when the vessel 
was successively stretched and a tension was given to the vessel. D is the diameter of the 
tungsten wire used for mounting the vessels.
B) Internal diameter (ID):
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ID (nm) = IC/II
C) The Laplace’s equation to determine the transmural pressure (P):
P (kPa) = T / {2L x IC / (2 n  x 1000)}
T (mN) is the tension reading on the myograph when stretching the vessel at the 
micrometer reading at Xi; L is the length of vessel ring (2mm). P is converted to mmHg 
if divided by 0.1333.
The resting tension was raised to give an equivalent transmural pressure of 12 - 16 
mmHg to the pulmonary artery rings in normoxic rats, approximately reflecting in vivo 
transmural pressures in pulmonary artery (McCulloch & MacLean, 1995). The resting 
tension was raised to an equivalent pressure of 25 - 30 mmHg for the pulmonary artery 
rings in CH rats (McCulloch et al., 1996).
Isometric tension responses to agonists were recorded through a Maclab computer 
system. At each concentration the tension was allowed to increase to a plateau before 
changing to the next concentration. 50mM KC1 was added first to test the viability of 
smooth muscle. Vessels were precontracted with lpM PHE and then followed by 3pM 
ACH to test the viability of the endothelial cells. Agonist-induced vasoconstrictor 
responses were standardized by expressing them as a percentage of the vasoconstrictor 
response to 50mM KC1 in the same vessel. Cumulative concentration-dependent 
contractions to KC1, PHE, Ang II were recorded in the fourth order branches of
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pulmonary arteries and/or the left pulmonary arteries. Vessels were thoroughly washed 
between each set of contractile responses to agonists.
2.8 Permeabilized pulmonary and mesenteric artery preparations
2.8.1 a-Toxin
a-Toxin which was isolated from Staphylococcus aureus strain Wood 46, can bind to cell 
membranes to form hydrophilic pores ( 1 - 2  nm diameter). These hydrophilic pores 
permit the passage of small molecules (up to lkDa) but prevent the loss of essential 
cytoplasmic proteins from the cells. Therefore, integral regulatory components such as 
calmodulin- and cyclic nucleotide-dependent protein kinases are maintained at 
physiological concentrations (Ohanian et a l , 1997).
Permeabilised arteries allow [Ca2+]i to be controlled by EGTA, a Ca2+ chelator, and yet 
receptors remain coupled to their intracellular signalling pathways. It provides a useful 
method for studying Ca2+ mobilization and Ca2+ sensitization. With the [Ca2+]j clamped 
and the intracellular stores depleted, any observed vasoconstriction could be only due to 
an increased sensitivity of the contractile apparatus to Ca2+ (Evans et al., 1999).
2.8.2 Permeabilization procedure
Male Wistar rats (200 - 250g) were killed by cervical dislocation. The heart and lung en
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bloc and a segment of the ileum with attached mesentery were removed and placed in 
Krebs’ solution. Pulmonary arteries were always obtained from upper left lobe to avoid 
variation. The fourth order branches of pulmonary arteries (2 mm length) and the third 
order branches of mesenteric arteries (2 mm length) were dissected in Krebs’ solution 
under a microscope. One long tungsten wire was passed through the vessel lumen for 
handling the vessels. The wire was bent at right angles at both sides to prevent the tissue 
slipping off.
The vessels were permeabilized with a-toxin (1000 haemolytic units/ml) in lOmM 
EGTA solution (called relaxing solution), and incubated in Eppendorf tubes for 30 min. 
The vessel with tungsten wire was removed from a-toxin solution and mounted on a 
myograph in relaxing solution and gassed with 95% 0 2 /5 % CO2 at room temperature (22 
- 25°C) for 30min without any initial tension. The tension on the permeabilized vessels 
was set up at lmN before drug administration (Evans et al., 1999; Hill et a l , 2000).
2.8.3 Demonstration of permeabilization
Permeabilization was assessed by vasoconstriction responses to Ca2+ (lOnM - lOpM), 
these concentrations of Ca2+ had no effect on the intact vessels. Ca2+ concentration- 
tension curves were obtained by mixing relaxing solution and Ca2+ EGTA solution 
(called contracting solution) or adding CaCb to 80nMCa2+/ 0.2mM EGTA solution 
(called refilling solution). Figure 2.5 shows a representative tracing of Ca2+-tension 
responses in a permeabilized pulmonary artery ring.
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Figure 2.5 Demonstration of permeabilization in the pulmonary artery
Ca2+ (10nM-10 pM) induced the vasoconstriction in the permeabilized pulmonary artery. Up to 
10 pM, Ca2+ did not induce any vasoconstriction in non-permeabilized pulmonary artery. Ca2+ 
was buffered by relaxing and contracting solutions. The peak responses are artefacts from 
changing solutions.
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A computer programme adapted from Fabiato and Fabiato (1979) by Dr. G.D. Smith 
(University of Glasgow) was used to calculate the equilibration concentrations of free 
metal ions and affinity constants relating to ionic strength and pH. Affinity constants for 
H+, Ca2+ and Mg2+ binding to EGTA were taken from Smith and Miller (1984). [Ca2+]i in 
mock intracellular solutions were estimated from the proportion of relaxing solution and 
contracting solution, according to equation:
[Ca2+]i = Kd x [relaxing solution/contracting solution]
Kd (affinity constant) for EGTA associated with Ca2+, which is influenced by 
temperature, pH, ionic strength and concentrations of heavy metals, was calculated using 
a computer program.
Examining the ability of intracellular Ca2+ stores in arteries to refill with the mock 
intracellular solution of minimal Ca2+ content (80nM Ca2+/0.2mM EGTA) also assessed 
the effectiveness of permeabilization. lOmM caffeine was applied to the arterial segment 
maintained in the mock intracellular solution and following wash out the caffeine was re­
applied at lOmin intervals. A repeatable caffeine-evoked contractile response,
*74-corresponding to intracellular store Ca release, was taken to demonstrate complete 
permeabilisation (Hill et al., 2000).
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2.9 Drugs and chemicals
Drugs were obtained from the following sources: ET-1 was obtained from Peptide 
Institute (Japan). BQ123 (cyclo[D-Asp-L-Pro-D-Val-L-Leu-D-Trp]) and BQ788 ([N-cis- 
2,6-dimethylpiperidinenocarbonyl-L-rMe-Leu-D-Trp (COOMe)-D-Nle-Ona]) were 
supplied by Rhone-Poulenc Rorer (Dagenham, England). PD156707 (sodium 2- 
benzo(l,3)dioxol-5-yl-4-(4-methoxy-phenyl)-4-oxo-3-(3,4,5-trimethoxy-benzyl)-but-2- 
enoate) was a generous gift from Parke-Davis Pharmaceutical Research, Ann Arbor, 
Michigan, USA. HOE642 (4-isopropyl-3-methyl-sulphonylbenzoyl-guanidine 
methanesulphonate) was a generous gift from Dr. H. J. Lang, Hoechst Pharmacuiticals. 5- 
HT, PHE, NA, Adr, heparin sulphate, Ang II, HEPES (N-2-hydroxyethylpiperaxine-N-2- 
ethanesulphonic acid), creatine phosphate, EGTA (ethylene glycol-bis(b- 
aminoethylether)-N,N,N’,N’-tetra acetic acid), prazosin, U46619 (9, 11-dideoxy-lla, 9a- 
epoxymethano-prostaglandin F2a) and ATP (adenosine 5’-triphosphate) were obtained 
from Sigma company. K+ proprionate was obtained from Phase Separation Ltd. 
Staphylococcus aureus a-toxin (haemolysin) and Ro-32-0432 (2-{8-
[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido [ 1,2-a] indol-3-yl} -3 -(1 -methylindol-3 - 
yl)maleimide, hydrochloride were obtained from Calbiochem. The chemicals for Krebs’ 
solution were obtained from BDH.
NA and Adr were dissolved in distilled water with ascorbic acid (KT4 M). ET-1 was 
dissolved in normal saline and stored at -20°C. BQ123, PD17567, staurosporine and 
corticosterone were dissolved in DMSO; the final concentration of DMSO in perfusate
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was less than 0.1%. U46619 was dissolved in 95% ethanol and stored at -80°C. a-Toxin 
was dissolved in distilled water and stored at 4°C. Caffeine (100 mM) was prepared in 












Krebs’ solution was prepared freshly. Potassium chloride, potassium dihydrogen 
phosphate, calcium chloride and magnesium sulphate were taken from stock solutions.
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lOmM for relaxing and 
contracting solutions, 
0.2mM for refilling 
solution
CaCl2 0.01Mx94.6pl 80nM
HEPES 500mMx5ml 500mMx5ml 500mMx5ml 25mM
MgCl2 700mMxlml 700mMxlml 700mMxlml 7mM
K propionate lMxlOml lMxlOml lMxlOml lOOmM
Na2ATP 0.312g 0.312g 0.312g 5M
Creatine P04 0.504g 0.504g 0.504g 15mM
Distilled Water 73.5ml 73.5ml 83.3ml
Total Volume 100ml 100ml 100ml
The pH of the mock intracellular solutions was adjusted to 7.0 with 1M KOH.
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2.10.3 Stock solutions for mock intracellular solutions
COMPOUNDS M.W. CONCENTRATION VOLUME (ml)
EGTA 368.98 lOOmM 100ml
Ca2+EGTA lOOmM (EGTA) 100ml
HEPES 238.3 500mM 100ml
MgCl2 203.3 700mM 100ml
K+ propionate 130 1M 100ml
KOH 56.11 1M 100ml
When preparing EGTA (lOOmMx 100ml) stock solution, 3.6898g EGTA was dissolved in 
20ml 1M KOH first, adding a small amount at a time meanwhile swirling it. 1M KOH 
was added if needed to fully dissolve EGTA.
When preparing Ca2+EGTA (lOOmM x 100ml) stock solution, 1.08g CaCC>3 was added 
in lOOmM x 100ml EGTA stock solution. CaC(> 3  was added gradually whilst swirling 
contents of beaker above low burning bunsen burner until bubbles (CO2) had come off 
and the solution was clear.
HEPES, MgCl2(6H20), potassium propionate and potassium hydroxide were prepared 
with distilled water. Na2ATP (MW605.19) and creatine PO4 (MW 255.1) were added 
freshly in relaxing solution or contracting solution.
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2.11 Statistics
All responses were plotted against doses/concentrations of vasoconstrictors on a 
logarithmic scale, using Origin (2.94 version) computer program. The potencies of drugs 
were expressed as ED5o which is the dose producing 50% of the maximum response to a 
particular agent.
All data shown were means ± s. e. means. Data were analyzed by unpaired Student’s t- 
test or paired Student’s t-test for two independant samples or comparison between paired 
data respectively. One-way analysis of variation (ANOVA) with Dunnett’s test was 
applied to data from more than two groups. The significance was accepted if P < 0.05. 





3.1 Pulmonary vascular reactivity during normoxia and CH
3.1.1 Effect of CH on indices of pulmonary hypertension
As indices of hypoxic pulmonary hypertension, haematocrit, basal PPP and ratio of right 
ventricular weight/total ventricular weight were investigated in CH rats and the weight- 
matched control rats.
As shown in Figure 3.1, haematocrit significantly increased from 43.2 ± 2.0% in the 
controls to 57.2 ± 1.0% in CH rats, P < 0.001, n = 10 - 13. Three weeks of hypoxia 
resulted in significant increases in the basal PPP from 6.3 ± 0.9mmHg in the controls to 
10.5 ± 0.2mmHg in CH rats, P < 0.01, n = 5 (Figure 3.2).
Figure 3.3 shows the ratio of right ventricular weight to total ventricular weight in the 
controls and CH rats. The ratio significantly increased from 0.21 ± 0.01 in the control rats 
to 0.33 ± 0.01 in CH rats, P < 0.001, n = 13 -15.
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Figure 3.1: Haematocrit in the normoxic and CH rats.
Blood samples were collected from the normoxic rats as the controls ( Q] ), weight-matched to
CH rats ( |  )• Each column represents mean ± s. e. mean. ***P < 0.001 vs. the controls;
unpaired Student's t-test. n = 10 for the control group and n = 13 for the CH group.
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Figure 3.2: Basal PPP during normoxia and CH in the isolated perfused lungs.
Basal PPP in CH rats ( |  ) was significantly higher than in the control group ( | | ). Each column 











Figure 3.3: Index of right ventricular hypertrophy in the normoxic and CH rats.
The ratio of right ventricular weight to total ventricular weight was taken as index of 
right ventricular hypertrophy in the normoxic ( 0  ) and CH ( |  ) rats. Each column 
represents mean ± s. e. mean. *** p < 0.001 vs. the controls; unpaired Student’s t-test. n 
= 13 for the control group and n = 15 for the CH group.
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3.1.2 Effect of CH on responses to PHE in isolated lungs
PHE was bolus-injected into the isolated perfused lungs through the pulmonary artery, 
and PPP was recorded in both CH lungs and the weight-matched controls. The 
vasoconstrictor responses to all doses of PHE (1 - 30 nmoles) were significantly 
enhanced in CH isolated perfused lungs when compared to the controls (Figure 3.4). For 
example, 10 nmoles PHE induced increases of PPP in the controls of 2.7 ± 0.3 mmHg (n 
= 7) and 15.4 ± 3.0 mmHg (n = 5) in CH rats, P < 0.01. However EDso values of the two 
groups were not significantly different.
In the isolated aortic rings, cumulative concentration-dependent contraction curves of 
PHE were built up from the weight-matched controls and CH rats. The contractile 
responses to PHE were not enhanced in the CH group (n = 7), compared to the control 




















Figure 3.4: Vasoconstrictor responses to PHE in normoxic and CH isolated perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of PHE ( 1 - 3 0  nmoles) into 
the lungs from normoxic ( □  ) and CH ( Q  ) animals. Each point represents mean ± s. e. mean. 
*P< 0.05 vs. the controls; **P < 0.01 vs. the controls; unpaired Student’s t-test. n = 9 for the 
normoxic rats and n = 11 for the CH rats.
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Figure 3.5: Concentration-dependent contractions to PHE in normoxic and CH isolated 
aortic rings.
Data are presented as increases of tension (mN) to cumulative concentrations of PHE ( 0.3 - 300 
nM) in the aortic rings from normoxic ( D  ) and CH ( ®  ) rats. Each point represents mean ± 
s. e. mean, n = 4 for the normoxic rats and n = 7 for the CH rats.
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3.1.3 Effect of different oxygen tensions on responses to PHE in CH isolated lungs
The isolated lungs from CH rats were perfused with Krebs’ solution bubbled with low 
oxygen (10% 02/85% N2/5% CO2). Low oxygen tension did not significantly change the 
vasoconstrictor responses to PHE in CH isolated perfused lungs, compared to the results 
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Figure 3.6: Effect of different oxygen tensions on vasoconstrictor responses to PHE in CH 
isolated perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of PHE (1 -100 nmoles) into 
the CH lungs perfused with 20% 02 ( □  ) or 10% O2  ( ®  ). Each point represents mean ± s. e. 
mean, n = 6 for each group.
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3.1.4 Effects of ET-1 receptor antagonists and ET converting enzyme inhibitor on
responses to PHE in CH isolated lungs
It was decided to see whether vascular synthesis of ET-1 modulated the vasoconstrictor 
responses to PHE during CH. ETa receptor antagonists, an ETb receptor antagonist and 
an ET converting enzyme inhibitor were used.
To confirm that the concentration of PD156707 (5 pM) was sufficient to block ETa 
receptors on the pulmonary vascular smooth muscle, the vasoconstrictor responses to ET- 
1 were recorded in the absence and presence of PD 156707. PD 156707 (5 pM) obviously 
inhibited the ET-1-induced vasoconstrictor responses in normoxic isolated perfused lungs 
(Figure 3.7). However, PD 15670 did not affect the vasoconstrictor responses to PHE in 
CH isolated lungs (Figure 3.8).
BQ788 had no effect on the basal PPP. Also BQ788 did not affect PHE-induced 
vasoconstrictor responses in CH isolated perfused lungs (Figure 3.9). PPP increases 
induced by 30nmoles PHE in the absence and presence of BQ788 (5 pM) were 8.4 ± 2.3 
mmHg and 6.9 ± 1.4, respectively (n = 5, P > 0.05).
Phosphoramidon (10 pM), an ET converting enzyme inhibitor also had no effect on the 
vasoconstrictor responses to PHE in CH isolated perfused lungs (P > 0.05, n = 4) (Figure 
3.10).
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The time course of PPP increases to PHE in CH isolated perfused lungs was also studied 
(Figure 3.11). Dose-responses to PHE were repeated after a 15 min interval, which is the 
same period as used for infusion of the antagonists. The two dose-response curves of 







Figure 3.7: Effect of a selective ETA receptor antagonist, PD156707 on the vasoconstrictor 
responses to ET-1 in the normoxic isolated perfused lungs.
The vasoconstrictor responses to ET-1 (100 - 400 pmoles) were recorded in the absence ) or
presence ( □  ) of PD 156707 (5 pM) in the normoxic isolated perfused lungs. Each point represents









Figure 3.8: Effect of a selective ETA receptor antagonist, PD156707 on the vasoconstrictor 
responses to PHE in CH isolated perfused lungs.
The vasoconstrictor responses to PHE (0.3 - 30 nmoles) were recorded in the absence ( Q  ) or
presence ( ®  ) of PD 156707 (5 pM) in CH lungs. Each point represents mean ± s. e. mean; n =
















Figure 3.9: Effect of a selective ETB receptor antagonist, BQ788 on the vasoconstictor 
responses to PHE in CH isolated perfused lungs.
The vasoconstrictor responses to PHE (1 - 100 nmoles) were recorded in the absence ( Q  ) or
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Figure 3.10: Effect of an ET converting enzyme inhibitor, phosphoramidon on the 
vasoconstrictor responses to PHE in CH isolated perfused lungs.
The vasoconstrictor responses to PHE (0.1 - 30 nmoles) were recorded in the absence ( | | ) or
presence ( ®  ) of phosphoramidon (10 pM) in CH isolated perfused lungs. Each point represents
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Figure 3.11: Reproducibility of the vasoconstrictor responses to PHE in CH isolated 
perfused lungs.
Bolus injections of PHE (0.1 - 100 nmoles) into CH lungs were repeated after a 15min interval 
( A  ) and compared with the original controls ( ®  ). Each point represents mean ± s.e.mean. n 
= 4 for each group.
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3.1.5 Effect of CH on responses to other agonists in isolated lungs
In order to see whether the enhanced vasoconstrictor responses in the CH isolated 
perfused lungs could be universal, a series of experiments were performed to investigate 
the effect of CH on the magnitude of vasoconstrictor responses to other agonists in 
isolated perfused lungs.
Table 3.1 summarizes increases in PPP induced by agonists in normoxic and CH isolated 
perfused lungs. All substances tested induced potentiated responses in CH isolated 
perfused lungs when compared with the controls, especially at high doses. But there is no 
difference in EDso values of the controls and CH lungs for any agonist.
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Table 3.1: Effect of CH on the vasoconstrictor responses in isolated perfused lungs.
A gonists D oses
PPP increase (mm Hg) EDso
Control (number) CH (number) C ontrol (num ber) CH (number)
PHE 10 nmol 2.4 ± 0.7 (9) 5.7 ± 0.8 (10)** 4 .4 1 1 .4  nmol (8) 5 .4 1 0 .9  nmol (10)
N A 1 nmol 2.7 ±  0.5 (6) 8.8 ± 1.9 (5)* 0.3 1 0 .0 1  nmol (5) 0 .4 1 0 .1  nmol (5)
Ang II 300 pmol 8.0 ± 1 .4  (4) 23.6 ± 4  (4)* 45 1 2 .9  pmol (3) 4 6 1 5  pmol (4)
U 46619 30 pmol 3.2 ±  1.1 (5) 7 .1 1 0 .6  (3)* s ' s '
KC1 200 pmol
8 .5 ± 1 .2  (6)
1 8 .7 1 3 .8 (5 )* s ' s '
Data are presented as increases of PPP (mmHg) to bolus injections of agonists into the lungs from 
normoxic and CH animals. PPP increases induced by all agonists were potentiated in CH isolated 
perfused lungs, compared to the controls. Due to pulmonary oedema at high doses of KC1 and 
U46619 the maximal responses and ED50 values to these two agonists were not obtained.
Each group of data represents mean ± s. e. mean. *P < 0.05 vs. the controls; **P < 0.01 vs. the 
controls; unpaired Student’s t-test.
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3.1.5.1 Effect of CH on responses to Ang II in isolated lungs
Ang II (1 -  300 pmoles) was tested in CH and control lungs. CH exposure potentiated 
Ang II-induced vasoconstrictor responses, compared to the controls (Figure 3.12). The 
threshold responses between CH and control lungs were not obviously different, only at 
high doses the vasoconstrictor responses to Ang II in CH lungs were enhanced. For 
example, 300 pmoles Ang II induced increases in PPP as 8.0 ±1.4 mmHg in the controls 
and 23.6 ± 4.6 mmHg in CH lungs, P < 0.05, n = 3 - 4.
BQ123 (5 pM), which reduced the potentiated vasoconstrictor responses to PHE in CH 
perfused lungs, had no effect on the vasoconstrictor responses to Ang II in the CH lungs 
















Figure 3.12: Vasoconstrictor responses to Ang II in normoxic and CH perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of Ang II (1 - 300 pmoles) into 
the lungs from normoxic ( Q  ) or CH ( |  ) animals. Each point represents mean ± s. e. mean. 
















Figure 3.13: Effect of an ETA receptor antagonist, BQ123 on the responses to Ang II in 
CH isolated perfused lungs.
The vasoconstrictor responses to Ang II (1 - 300 pmoles) were recorded in the absence ( | | )
or presence ( ®  ) of BQ123 (5 pM) in CH lungs. Each point represents mean ± s. e. mean, n
= 4 for each group.
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3.1.5.2 Effect of CH on responses to KC1 in isolated lungs
KC1 (25 -  400 pmoles) was also tested in isolated perfused lungs. CH significantly 
increased KCl-induced vasoconstrictor responses in isolated perfused lungs (Figure 3.14). 
200 pmoles KC1 increased PPP from 8.5 ±1.2 mmHg in the controls to 18.7 ± 3.8 mmHg 
in the CH lungs, P < 0.05, n = 5 - 6. The threshold doses of KC1 in CH and the control 
group were not different. The response to maximal dose of KC1 was not recorded because 
the isolated perfused lungs became oedematous quickly with high doses of KC1.
The vasoconstrictor responses to KC1 in CH lungs were not affected by BQ123 (5 pM) or 




















Figure 3.14: Vasoconstrictor responses to KC1 in normoxic and CH perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of KC1 (25 - 400 pmoles) 
into the lungs from the normoxic ( □  ) and CH ( Q )  animals. Each point represents mean ± 
s. e. mean. *P < 0.05 vs. the controls; **P < 0.01 vs. the controls; unpaired Student’s t-test. n 
= 5 - 6 for the normoxic and CH rats.
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Figure 3.15: Effect of ETA receptor antagonist, BQ123 and ETB receptor antagonist, BQ788 on 
KCI-induced vasoconstrictor responses in CH isolated perfused lungs.
The vasoconstrictor responses to KC1 (200 pmoles) were recorded in the controls ( |  ) or in the 
presence of BQ123 (5 pM) ( |  ) or BQ788 (5 pM) ( p  ) in CH isolated perfused lungs. Each column 
represents mean ± s. e. mean, n = 4 for each group.
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3.1.5.3 Effect of CH on responses to NA and U46619 in isolated lungs
Figure 3.16 shows the vasoconstrictor responses to NA in the isolated perfused lungs. 
Similar to PHE, NA-induced vasoconstrictor responses were potentiated in the isolated 
perfused lungs from CH animals, compared to the controls. 1 nmole NA produced 
increases in PPP of 2.7 ± 0.5 mmHg in the controls and 8.8 ±1.9 mmHg in the CH lungs, 
respectively (P < 0.05, n = 5 - 6).
The vasoconstrictor responses to U46619 (1 -  30 pmoles) were also potentiated in CH 
perfused lungs (Figure 3.17). 30 pmoles U46619 increased PPP of 3.2 ± 1.1 mmHg in the 
controls vs. 7.1 ± 0.6 mmHg in the CH lungs (P < 0.05, n = 3 - 5). The response to 
maximal dose of U46619 was not recorded because the isolated perfused lungs became 








Figure 3.16: Vasoconstrictor responses to NA in the normoxic and CH perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of NA (0.1 - 10 nmoles) into 
the lungs in normoxic o  ) and CH ( Q )  animals. Each point represents mean ± s. e. mean. *P < 




















Figure 3.17: Vasoconstrictor responses to U46619 in normoxic and CH perfused lungs.
Data are presented increases of PPP (mmHg) to bolus injections of U46619 (1 -30 pmoles) into 
lungs in normoxic ( □  ) and CH ( Q  ) animals. Each point represents mean ± s. e. mean. *P < 
0.05 vs. the controls; unpaired Student’s t-test. n = 5 for the normoxic rats and n = 3 for the CH 
rats.
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3.1.6 Comparison of vascular reactivity between large and small pulmonary arteries
As a large pulmonary artery, the left pulmonary artery (ID: 1059 ± 95 pm, n = 7) was 
chosen and the fourth order branch of the pulmonary artery (ID: 234 ± 20 pm, n = 7) was 
taken as a small pulmonary artery. The vessels were mounted on wire myograph and the 
basal tension was set up at 4.1 ± 0.3 mN (n = 7) for the large pulmonary arteries and 1.1 
± 0.1 mN (n = 9) for the small pulmonary arteries, mimicking the transluminal tension in 
the pulmonary artery of 12 - 16mmHg in vivo.
KC1 induced concentration-dependent contractions in both large and small pulmonary 
arteries. Contraction to 50 mM KC1, a sub-maximal concentration was chosen for 
standardising the vasoconstrictor responses to all vasoconstrictors in the same 
preparation. The absolute values of vasoconstrictor responses to KC1 are greater in the 
large pulmonary arteries than the small pulmonary arteries. However, there was no 
difference in standardised concentration-dependent contraction curves to KC1 in the large 
and small pulmonary arteries (Figure 3.18).
PHE induced concentration-dependent contractions in the large pulmonary arteries. 
However, in the small pulmonary arteries, much smaller responses were observed. The 
maximal contraction to PHE (1 pM) was 83 ± 10 % (n = 6) in the large pulmonary 
arteries and 24.2 ± 9.3 % (n = 6) in the small pulmonary arteries, P < 0.01 (Figure 3.19).
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Ang II contracted in both sizes of the pulmonary artery rings. In contrast with the 
responses to PHE, the vessels desensitised to Ang II very quickly (Figure 3.20). The 
contractile responses to Ang II were diminished in the small pulmonary arteries 
compared to the large ones, although there was no significant difference between the 
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Figure 3.18: Concentration-dependent contractions to KC1 in large and small pulmonary 
arteries from normoxic rats.
Vascular responses to KC1 (5-100 mM) in the large ( □  ) or small (▲  ) pulmonary artery rings 
are expressed as a percentage of contraction to 50 mM KC1 in the same preparation. Each point 
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Figure 3.19: Concentration-dependent contractions to PHE in large and small pulmonary 
arteries from normoxic rats.
Vascular responses to PHE (1 - 1000 nM) in large ( □  ) or small ( ▲  ) pulmonary artery rings 
are expressed as a percentage of contraction to 50 mM KC1 in the same preparation. Each point 
represents mean ± s. e. mean. **P < 0.01 vs. the large pulmonary arteries; unpaired Student’s t- 












Figure 3.20: Concentration-dependent contractions to Ang II in large and small pulmonary 
arteries from normoxic rats.
Responses to cumulative concentrations of Ang II (1 -100 nM) in large ( □  ) or small (▲  ) 
pulmonary artery rings are expressed as a percentage of contraction to 50 mM KC1 in the same 
preparation. Each point represents mean ± s. e. mean, n = 6 for the large pulmonary arteries and 
n = 7 for the small pulmonary arteries.
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3.1.7 Effect of CH on vascular reactivity in pulmonary resistance arteries
To investigate the effect of CH in isolated pulmonary resistance arteries, vasoconstrictor 
responses were investigated in the fourth order branches of pulmonary artery from 
normoxic and CH rats.
The contractile responses to KC1 and PHE were similar in pulmonary resistance arteries 
from the normoxic and CH rats (Figure 3.21 & 3.22). The contractile responses observed 
to 5-HT were potentiated in the pulmonary resistance arteries from 
CH rats compared to the controls (Figure 3.23). The maximal responses to 5-HT (100 
pM) were 41.3 ± 9.2 % (n = 3) in the controls and 168.6 ± 33.3 % (n = 5) in CH, P < 
0.05. Conversely, the responses to Ang II were diminished in the pulmonary resistance 
arteries from CH rats compared to the controls; 48.8 ± 12.3 % (n = 4) in CH rats vs. 9.8 ± 
3.8 % (n = 5) in the controls to 10 nM Ang II, P < 0.05 (Figure 3.24).
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Figure 3.21: Responses to KC1 in pulmonary resistance arteries from normoxic and CH 
rats.
Vascular responses to KC1 (5-100 mM) in pulmonary resistance arteries from normoxic ( 
or CH ( ®  ) rats are expressed as a percentage of contraction to 50 mM KC1 in the same 
preparation. Each point represents mean ± s. e. mean, n = 3 for the controls and n = 5 for CH 
group.
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Figure 3.22: Responses to PHE in pulmonary resistance arteries from normoxic and CH rats.
Increases of tension to cumulative concentrations of PHE (1 - 1000 nM) in pulmonary resistance 
arteries from normoxic ( □  ) or CH ( ®  ) rats are expressed as a percentage of contraction to 
50mM KC1 in the same preparation. Each point represents mean ± s. e. mean, n = 3 for the controls 
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Figure 3.23: Responses to 5-HT in pulmonary resistance arteries from normoxic and hypoxic 
rats.
Responses to cumulative concentrations of 5-HT (0.3 -100 pM) in pulmonary resistance arteries 
from normoxic ( D  ) or CH ( ®  ) rats are expressed as a percentage of contraction to 50 mM KC1 
in the same preparation. Each point represents mean ± s. e. mean. *P < 0.05 vs. the controls; **P < 




















Figure 3.24: Responses to Ang II in pulmonary resistance arteries from normoxic and hypoxic 
rats.
Vascular responses to Ang II (1 -100 nM) in pulmonary resistance arteries from normoxic ( | | ) or 
CH ( ®  ) rats are expressed as a percentage of contraction to 50 mM KC1 in the same preparation. 
Each point represents mean ± s. e. mean. *P < 0.05 vs. the controls; unpaired Student’s t-test. n = 5 for 
the controls and n = 4 for CH group.
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3.2 Relationship between pulmonary vascular hyper-reactivity and pulmonary
vascular remodelling in CH
3.2.1 Preliminary experiments for time-dependent study of vasoconstrictor 
responses in isolated lungs
Initial experiments were carried out to ascertain the course of pulmonary hyper-reactivity 
during hypoxia and the recovery period. Three agonists (PHE, Ang II and KC1) were 
tested in this study.
The vasoconstrictor responses to PHE in isolated perfused lungs after 3 days and 7 days 
hypoxia were similar to the controls. PHE-induced vasoconstrictor responses started to 
increase after 14 days hypoxia and were significantly higher after 21 days hypoxia than 
the controls. For example, 10 nmoles PHE induced increases of PPP of 15.4 ± 3.0 mmHg 
(n = 5) after 21 days hypoxia and 2.7 ± 0.3 mmHg (n = 7) in the controls, P < 0.05. The 
vasoconstrictor responses to PHE declined gradually after 3 days and 7 days recovery. 
After 14 days recovery, PHE responses had returned to the control levels. PPP increases 
induced by 10 nmoles PHE were 3.6 ± 0.6 mmHg (n = 6) after 14 days recovery (Figure 
3.25 & 3.26).
Hypoxia gradually potentiated the vasoconstrictor responses to Ang II as the duration of 
hypoxia increased. After 7 days hypoxia, the PPP increases induced by Ang II were 
significantly different from the controls. For example, 100 pmoles Ang II induced the
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increases of PPP as 6.8 ±1.1 mmHg in the controls (n = 4) and 17.3 ± 3.7 mmHg in at 21 
days hypoxia (n = 5), P < 0.05. During the recovery from 21 days hypoxia, the 
vasoconstrictor responses to Ang II were still higher than in normoxia. Increases in PPP 
induced by Ang II were still similar to 21 days hypoxia, even after 21 days recovery (12.0 
±1.3 mmHg to 100 pmoles Ang II, n = 6) (Figure 3.27 & 3.28).
The vasoconstrictor responses to KC1 in the isolated lungs after 3 days and 7 days 
hypoxia were similar to the controls. After 14 days hypoxia, KC1 responses started to 
increase. The significant increases appeared after 21 days hypoxia. Responses did not 
reverse to the control level even after 21 days recovery. For example, PPP increases to 
200 pmoles KC1 were 8.5 ±1.2 mmHg (n = 6) in the controls, 18.7 ± 3.8 mmHg (n = 5) 
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Figure 3.25: Vasoconstrictor responses to PHE in isolated perfused lungs from normoxic 
rats and those exposed to different periods of hypoxia.
Data are presented as increases of PPP (mmHg) to bolus injections of PHE (1-30 nmoles) 
into the lungs from normoxic ( Q  ), 3 days hypoxic ( 0  ), 7 days hypoxic ( Q  ), 14 days 
hypoxic ( ^  ) and 21 days hypoxic ( ^  ) animals. Each point represents mean ± s. e. mean. 



















Figure 3.26: Vasoconstrictor responses to PHE in isolated perfused lungs from normoxic 
rats, 21 days hypoxic rats and those exposed to different periods of recovery.
Data are presented as increases of PPP (mmHg) to bolus injections of PHE ( 1-30 nmoles) 
into the lungs from normoxic ( Q  ), 21 days hypoxic ( ®  ), 3 days recovery ( A x  7 days 
recovery ( ^  ), 14 days recovery ) and 21 days recovery (  - \ -  )  animals. Each point 
represents mean ± s. e. mean. *P < 0.05 vs. the normoxic group; one-way ANOVA with 
Dunnett’s test, n = 5 - 6 for each group. Re-use data from normoxic and 21 days hypoxic rats 
as negative and positive controls, respectively.
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Figure 3.27: Vasoconstrictor responses to Ang II in isolated perfused lungs from normoxic 
rats and those exposed to different periods of hypoxia.
Data are presented as increases of PPP (mmHg) to bolus injections of Ang II ( 1-300 pmoles) into 
the lungs from normoxic ( E ] ), 3 days hypoxic ( 0  ), 7 days hypoxic ( A  ), 14 days hypoxic (▼  
) and 21 days hypoxic ( 0  ) animals. Each point represents mean ± s. e. mean. *P < 0.05 vs. the 
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Figure 3.28: Vasoconstrictor responses to Ang II in isolated perfused lungs from 
normoxic rats, 21 days hypoxic rats and those exposed to different periods of recovery.
Data are presented as increases of PPP (mmHg) to bolus injections of Ang II ( 1 - 300 pmoles) 
into the lungs from normoxic ( □  ), 21 days hypoxic ( ®  ), 3 days recovery ( A j .  7 days 
recovery < ▼ ) .  14 days recovery ( A  ) and 21 days recovery ( +  ) animals. Each point 
represents mean ± s. e. mean. *P < 0.05 21 days hypoxic group and 3 days recovery group vs. 
the normoxic group; one-way ANOVA with Dunnett’s test, n = 5 - 6 for each group. Re-use 
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Figure 3.29: Vasoconstrictor responses to KC1 in isolated perfused lungs from normoxic rats 
and those exposed to different periods of hypoxia.
Data are presented as increases of PPP (mmHg) to bolus injections of KC1 (25 - 400 pmoles) into 
the lungs from normoxic ( □  ), 3 days hypoxic ( Q  ), 7 days hypoxic ( ^  ), 14 days hypoxic ( ^T) 
and 21 days hypoxic ( ^  ) animals. Each point represents mean ± s. e. mean. *P < 0.05 vs. the 
normoxic group; one-way ANOVA with Dunnett’s test, n = 4 - 6 for each group.
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Figure 3.30: Vasoconstrictor responses to KC1 in isolated perfused lungs from normoxic 
rats, 21 days hypoxic rats and those exposed to different periods of recovery.
Data are presented as increases of PPP (mmHg) to bolus injections of KC1 (25 - 400 pmoles) 
into the lungs from normoxic ( Q  ), 21 days hypoxic ( ®  ), 3 days recovery ( A ) ,  7 days 
recovery ( A ), 14 days recovery ( A  ) anc  ^21 days recovery ( +  ) animals. Each point 
represents mean ± s. e. mean. *P < 0.05 21 days hypoxia or 3 days recovery vs. the normoxic 
group; one-way ANOVA with Dunnett’s test, n = 5 - 6 for each group. Re-use data from 
normoxic and 21 days hypoxic rats as negative and positive controls, respectively.
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3.2.2 Indices of hypoxic pulmonary hypertension after 21 days hypoxia and 21 days 
recovery
As determined from the preliminary experiments, 21 days hypoxia and 21 days recovery 
rats were chosen for comparison of pulmonary vascular hyper-reactivity and pulmonary 
remodelling in CH.
Body weights were 300 ± 9.5g (n = 5) in the rats after 21 days hypoxia, 285.5 ± 6.1g (n = 
11) in the age-matched controls; 408.6 ± 13g (n = 5) in the recovery rats and 419.2 ± 9.6g 
(n = 12) in the age-matched controls.
Figure 3.31 shows the haematocrits during normoxia, after 21 days hypoxia and 21 days 
recovery. 21 days hypoxia increased haematocrit significantly from 46.5 ± 0.6% (n = 4) 
in the controls to 57 ± 0% (n = 4) after 21 days hypoxia (P < 0.05). After 21 days 
recovery, haematocrit returned to 49 ± 1.4%, similar to the normoxic level (P > 0.05, n = 
4).
Basal PPP increased from 6.3 ± 0.9 mmHg (n = 5) in the controls to 10.5 ± 0.2 mmHg (n 
= 5) after 21 days hypoxia (P < 0.05). After 21 days recovery, the basal PPP returned to a 
level (6.4 ± 0.5mmHg, n = 6) similar to the controls, P > 0.05 (Figure 3.32).
21 days hypoxia induced significant right ventricular hypertrophy as measured by the 
ratio of right ventricular weight to total ventricular weight; 0.205 ±0.013 in the controls
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vs. 0.338 ± 0.010 after 21 days hypoxia, P < 0.05. The ratio was still significantly 
elevated afer 21 days recovery (0.270 ± 0.019) as compared to the control group, P < 
0.05, n = 5 - 6 (Figure 3.33).
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Figure 3.31: Haematocrit in normoxic, 21 days hypoxic and 21 days recovery rats.
Blood samples were collected from the normoxic ( [[] ), 21 days hypoxic ( |  ) and 21 days 
recovery ( |  ) rats. Each column represents mean ± s. e. mean, *P < 0.05 vs. the normoxic group; 
one-way ANOVA with Dunnett’s test, n = 4 for each group.
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Figure 3.32: Basal PPP in isolated perfused lungs from normoxic, 21 days hypoxic and 21 days 
recovery rats.
Basal PPP in 21 days hypoxic rats ( |  ) was significantly higher than in the control group ( Q  ). 
After 21 days recovery, basal PPP was returned to a level ( | ) similar to the controls. Each column 
represents mean ± s. e. mean. *P < 0.05 vs. the normoxic group; one-way ANOVA with Dunnett’s 
test, n = 5 - 6 for each group.
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Figure 3.33: Index of right ventricular hypertrophy from normoxic, 21 days hypoxic and 21 
days recovery rats.
The ratio of right ventricular weight to total ventricular weight was taken as index of right ventricular 
hypertrophy from the normoxic ( j^ | ), 21 days hypoxic ( |  ) and 21 days recovery ( |  ) rats. 
Each column represents mean ± s. e. mean. *P < 0.05 vs. the normoxic group; one-way ANOVA with 
Dunnett’s test, n = 5 - 6 for each group.
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3.2.3 Effect of CH on structural changes of pulmonary vascular wall thickness
Figure 3.34 shows the typical micrographs of pulmonary arteries, which were similar size 
vessels from normoxic, 21 days hypoxic and 21 days recovery rats. The medial wall 
thickness of pulmonary arteries significantly increased in 21 days hypoxic rats. There are 
more vascular smooth muscle cells and elastic laminae in the pulmonary arterial wall 
after 21 days hypoxia, compared to the control; and the internal elastic lamina of the 
pulmonary artery is much clearer in 21 days hypoxic lungs than in the normoxic vessel. 
The hyperplasia of the vascular smooth muscle cells and increased elastic laminae were 
still apparent after 21 days recovery. 21 days hypoxia increased the medial wall thickness 
at all levels of pulmonary artery (Table 3.2). The pulmonary medial wall thickness was 
significantly increased from 17.5 ± 1% (n = 84) in the controls to 21.8 ± 0.9% (n = 106) 
after 21 days hypoxia, P < 0.01. After 21 days recovery, the pulmonary medial wall 
thickness (25.7 ± 1%, n = 89) was still higher than the age-matched control group (18.4 ± 
0.7%, n = 114), P < 0.001 (Figure 3.35).
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Figure 3.34: Pulmonary vascular remodellings after 21 days hypoxia and 21 days recovery
Representative fluorescence micrographs (x 400 magnification) show that in the age-matched 
control lungs (A), the pulmonary arterial walls are thin and 21 days hypoxia (C) induces pulmonary 
vascular hyperplasia including proliferation o f vascular smooth muscle cells (VSMC) and increase of 
elastic lamina (EL). During 21 days recovery (D), pulmonary vascular hyperplasia is still apparent 
compared to the age-matched controls (B).
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Table 3.2 Measurement of medial wall thickness and diameter of pulmonary arteries
Control (10W ) 21 days hypoxia C ontrol (13W ) R ecovery
Total vessels
No. of rats 4 5 5 4
No. of vessels 84 106 114 89
Ratio of wall thickness (%) 17.5 ±1 21.8 ±0.9** 18.4 ±0.7 25.7 ±1***
Vessel diameter (pm) 143.7 + 6.5 193 ± 10*** 176.9 ±9.1 151 ±13*
Diameter range (pm) 55 - 287 45 - 492 37 - 622 37-815
Vessel diameter < 150 pm
No. of vessels 50 45 61 56
Ratio of wall thickness (%) 17.6 ±1 24.2 ±1.6*** 20.1 ±1.0 27.6 ±1.7***
Vessel diameter (pm) 105.7 ±3.8 99 ± 3.4* 108.6 ±3.4 82 ±4.1***
Diameter range (pm) 55-147 45-147 37-149 37-147
Vessel diameter > 150 pm
No. of vessels 34 61 53 33
Ratio of wall thickness (%) 13.8 ±1.2 20 ± 0.9*** 16.5 ±0.9 22.5 ±1.8**
Vessel diameter (pm) 199.6 ±8.6 261.9 ±11*** 256 ±12 268 ± 23*
Diameter range (pm) 155-287 160-492 150-622 151 -815
The vessel number on each slide is 6-10. The age-matched controls to 21 day hypoxia were 10 
weeks rats; whereas the age-matched controls to 21 days recovery were 13 weeks rats. Data for 
the ratio of wall thickness and vessel diameter are mean ± s. e. mean. *P < 0.05 vs. the age- 
matched controls; **P < 0.01 vs. the age-matched controls; ***P < 0.001 vs. the age-matched 














Figure 3.35: Pulmonary medial wall thickness in normoxic, 21 days hypoxic and 21 days 
recovery rats.
Ratio of pulmonary medial wall thickness was measured from the normoxic rats ( □  ). age- 
matched to 21 days hypoxic ( |  ) or 21 days recovery ( |  ) rats. Each column represents mean 
± s. e. mean. **P < 0.01 vs. the age-matched controls; ***P < 0.001 vs. the age-matched controls; 
unpaired Student’s t-test. n = 106 for 21 days hypoxia group and n = 84 for its age-matched controls, 
n = 89 for 21 days recovery group and n = 114 for its age-matched controls. Data were shown in 
Table 3.2.
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3.3 ET-1 sensitization in pulmonary vasculature
3.3.1 Determination of the sub-threshold concentration of ET-1 infusion in isolated 
lungs.
Initial experiments were carried out to determine a sub-threshold concentration of ET-1 
in the isolated perfused lungs. Figure 3.36 shows the concentration-vasoconstriction 
response curve produced by ET-1. 0.3 nM and InM ET-1 did not change PPP. PPP 
started to increase from infusion of 3nM ET-1, which induced a significant increase (10.9 
± 0.6 mmHg) when compared with the control group (8.5 ± 0.6 mmHg), P < 0.05, n = 4.
Another fact, which can affect ET-1 sensitization to vasoconstrictors, is the duration of 
ET-1 infusion. Figure 3.37 shows that from 30 min infusion of ET-1 (1 nM), ET-1 
significantly potentiated the vasoconstrictor responses to Ang II (30 pmoles) compared to 
the controls; 3.4 ± 0.5 mmHg for 30 min infusion of ET-1 vs. 1.6 ± 0.3 mmHg for 0 min 
infusion of ET-1, n = 7, P < 0.05.
Thus, in all subsequent experiments InM ET-1 had being infused into the pulmonary 





Figure 3.36: Effect of ET-1 on basal PPP in the isolated perfused lungs.
Isolated perfused lungs were perfused with Krebs’ solution as the controls (Q] ) or with infusion 
o f 0.3 nM ET-1 ( g  ), 1 nM ET-1 ( | g ) or 3 nM ET-1 ( | ) for 15 min. Each column 
represents mean ± s. e. mean. *P < 0.05 vs. the controls; one way ANOVA followed by 
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Figure 3.37: Effect of varying infusion times of ET-1 on Ang II-induced vasoconstrictor 
responses in isolated perfused lungs.
Graph shows effects of infusing ET-1 (1 nM) over various time points on responses to Ang II 
(30 pmoles), compared to the controls (no ET-1 infusion, time 0). Each point represents mean 
± s. e. mean. * P < 0.05 vs. 0 min infusion of ET-1; one way ANOVA followed by Dunnett’s 
test, n = 7 for each point.
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3.3.2 Effect of ET-1 on responses to Ang II in isolated lungs
Dose-responses to Ang II in isolated perfused lungs from normoxic rats were recorded 
before and after infusing the sub-threshold vasoconstrictor concentration of ET-1 (1 nM) 
for 30 minutes. The dose-response curve of Ang II was shifted to the left when infusing 
ET-1, compared with the controls (Figure 3.38). Responses to 10 pmoles Ang II were 
increased by ET-1 from 0.99 ± 0.17 mmHg in controls to 2.57 ± 0.42 mmHg with ET-1 
(n = 8, p < 0.05).
The antagonists were infused for 15 min and the duration of ET-1 infusion for sensitizing 
the pulmonary vasculature was still 30 min before bolus-injection of agonists. PD156707, 
a selective ETa receptor antagonist, and BQ788, a selective ETb receptor antagonist, both 
inhibited the potentiation of the vasoconstrictor responses to Ang II with ET-1 in the 
isolated perfused lungs from normoxic rats (Figure 3.39 & 3.40). The vasoconstrictor 
responses to 10 pmoles Ang II with ET-1 were reduced by PD156707 (5 pM) from 2.57 
± 0.42 mmHg in the ET-1 controls to 0.95 ± 0.24 mmHg with ET-1 plus PD156707 (n = 
4 - 8, P < 0.01). BQ788 (5 pM) shifted the vasoconstrictor responses to 10 pmoles Ang II 
from 2.57 ± 0.42 mmHg in ET-1 controls to 0.93 ± 0.33mmHg with ET-1 plus BQ788 (n 
= 5 - 8, P < 0.05).
Neither PD156707 (5 pM) nor BQ788 (5 pM) had any effect on the vasoconstrictor 
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Figure 3.38: Effect of ET-1 on vasoconstrictor responses to Ang II in normoxic isolated 
perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of Ang II (1 - 300 pmoles) into 
the lungs in the controls ( D  ) or with ET-1 (InM) (®  ). Each point represents mean ± s. e. 
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Figure 3.39: Effect of a selective ETA receptor antagonist, PD156707 on the 
vasoconstrictor responses to Ang II with ET-1 in normoxic isolated perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of Ang II (1 -100 pmoles) 
into the lungs with ET-1 alone (InM) ( H  ) or with ET-1 plus PD156707 (5 pM) ( O ).
Each point represents mean ± s. e. mean. *P < 0.05 vs. ET-1 controls; **P < 0.01 vs. ET-1 
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Figure 3.40: Effect of a selective ETB receptor antagonist, BQ788 on the vasoconstrictor 
responses to Ang II with ET-1 in normoxic isolated perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of Ang II (1 -100 pmoles) 
into the lungs with ET-1 alone (InM) ( H  ) or with ET-1 plus BQ788 (5 pM) ( O ). Each 
point represents mean ± s. e. mean. *P < 0.05 vs. ET-1 controls; unpaired Student’s t-test. n = 
8 for ET-1 controls and n = 5 for BQ788 treated group.
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3.3.3 Effect of staurosporine and RO-32-0432 on ET-1 sensitization to responses in
isolated lungs
Staurosporine, a non-selective PKC inhibitor and RO-32-0432, a selective PKC inhibitor 
were investigated on ET-1 sensitization of the vasoconstrictor responses to Ang II. As the 
controls, the vasoconstrictor responses to Ang II were recorded when InM ET-1 had been 
infused for 30 min. After infusion of InM ET-1 for 30 min plus infusion of staurosporine 
or RO-32-0432 for the last 15 min, dose-responses to Ang II were recorded as the treated 
groups.
Staurosporine reduced the potentiated vasoconstrictor responses to Ang II by ET-1 in the 
isolated perfused lungs from normoxic rats (Figure 3.41). PPP increases to 100 pmoles 
Ang II with ET-1 were reduced by staurosporine (100 nM) from 10.8 ± 0.7 mmHg (n = 
8) in ET-1 controls into 1.5 ± 0.2 mmHg (n = 3) with ET-1 plus staurosporine (P < 
0.001). However, RO-32-0432 (100 nM) did not attenuate the potentiation effect of ET-1 

















Figure 3.41: Effect of a non-selective PKC inhibitor, staurosporine on the responses to 
Ang II with ET-1 in normoxic isolated perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of Ang II (1 - 100 
pmoles) into the lungs with ET-1 alone (1 nM) ( H )  or with ET-1 plus staurosporine (100 
nM) (O )• Each point represents mean ± s. e. mean. **P < 0.01 vs. ET-1 controls, ***P < 
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Figure 3.42: Effect of a selective PKC inhibitor, RO-32-0432 on the responses to Ang 
II with ET-1 in normoxic isolated perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of Ang II (1 - 100 
pmoles) into the lungs with ET-1 alone (InM) ( H  ) or with ET-1 plus RO-32-0432 (100 
nM) ( o  ). Each point represents mean ± s. e. mean, n = 4 for each group.
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3.3.4 Effects of HOE642 on ET-1 sensitization to vasoconstrictor responses in
isolated lungs
HOE642, a selective Na+/H+ exchanger inhibitor was tested on ET-1 sensitization of the 
vasoconstrictor responses Ang II to in isolated perfused lungs. HOE642 (10 pM) had no 
effect on the potentiation of ET-1 on the vasoconstrictor responses to Ang II (Figure 
3.43).
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Figure 3.43: Effect of a selective Na+/H+ exchanger inhibitor, HOE642 on the 
vasoconstrictor responses to Ang II with ET-1 in normoxic isolated perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of Ang II (1 -100 pmoles) 
into the lungs with ET-1 alone (InM) ( H ) or with ET-1 plus HOE642 (10 pM) ( O ). Each 
point represents mean ± s. e. mean, n = 4 - 5 for each group.
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3.3.5 Effect of ET-1 on responses to PHE in isolated lungs
Vasoconstrictor responses to PHE were also investigated in the presence of ET-1. Similar 
to Ang II, the dose-response curve of PHE was shifted to the left (Figure 3.44), compared 
with the control. PPP increases to 1 nmole PHE in the controls and group with ET-1 were 
1.9 ± 0.3 mmHg and 2.7 ± 0.2 mmHg, respectively; the responses to 3 nmoles PHE were 
increased by ET-1 from 2.2 ± 0.4 mmHg in the controls into 3.3 ± 0.4 mmHg (n = 8, P < 
0.05). But ED50S of the two groups were not significantly different, 1.7 ± 0.6 nmoles (n = 
7) in the controls and 0.6 ± 0.2 nmoles (n = 4) in the group with ET-1.
To demonstrate the potentiated vasoconstrictor responses to PHE were due to ET-1, time- 
matched responses to PHE were also recorded. Bolus injections of PHE were repeated 
after 30 min, which was the same period as infusion of ET-1. However the second dose- 
response curve of PHE did not differ from the first one (P > 0.05, n = 5) (Figure 3.45).
The role of ET receptors in ET-1 sensitization to PHE-induced vasoconstrictor responses 
in the isolated perfused lungs was also investigated. Neither PD156707 (5 pM) nor 
BQ788 (5 pM) affected the vasoconstrictor responses to PHE alone. However, both 
PD156707 and BQ788 shifted the vasoconstrictor response curve to PHE with 1 nM ET- 
1 to the right (Figure 3.46 & 3.47). PPP increases to 10 nmoles PHE with ET-1 were 
reduced by PD156707 (5 pM) from 3.86 ± 0.45 mmHg in ET-1 controls to 1.91 ± 0.26 
mmHg in PD156707 treated group (n = 4 - 12, P < 0.01). BQ788 (5 pM) shifted PPP
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increases by 10 nmoles PHE with ET-1 from 3.86 ± 0.45 mmHg to 2.01 ± 0.57 mmHg (n 
= 5 -12, P < 0.05).
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Figure 3.44: Effect of ET-1 on vasoconstrictor responses to PHE in normoxic isolated perfused 
lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of PHE ( 0.3 - 30 nmoles) into 
the lungs in the controls ( □  ) and with ET-1 (InM) ( ®  ) group. Each point represents mean ± s. 
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Figure 3.45: Time-matched study of vasoconstrictor responses to PHE in normoxic isolated 
perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of PHE (0 .1-100 nmoles) 
into the lungs in the controls ( □  ) and repeated after 30 min ( 9  ). Each point represents 
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Figure 3.46: Effect of a selective ETA receptor antagonist, PD156707 on the 
vasoconstrictor responses to PHE with ET-1 in normoxic isolated perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of PHE (0.3 - 30 nmoles) 
into the lungs with ET-1 alone (InM) ( B  ) or with ET-1 plus PD156707 (5 pM) ( O ). Each 
point represents mean ± s. e. mean. *P < 0.05 vs. ET-1 controls; **P < 0.01 vs. ET-1 controls; 












Figure 3.47: Effect of a selective ETB receptor antagonist, BQ788 on vasoconstrictor 
responses to PHE with ET-1 in normoxic isolated perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of PHE (0.3 - 30 nmoles) 
into the lungs with ET-1 alone (InM) ( H  ) or with ET-1 plus BQ788 (5 pM) ( O ). Each 
point represents mean ± s. e. mean. *P < 0.05 vs. ET-1 controls; unpaired Student’s t-test. n = 
12 for ET-1 controls and n = 5 for BQ788 treated group.
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3.3.6 Effect of ET-1 on responses to KC1 in isolated lungs
KC1 (25 - 400 pmoles) was also tested during infusion of ET-1 in isolated perfused lungs. 
Dose-responses to KC1 were recorded before and after infusing the sub-threshold 
vasoconstrictor concentration of ET-1 (InM) for 30 minutes. ET-1 did not change KC1- 
induced vasoconstrictor responses in the isolated perfused lungs from normoxic rats, P > 
0.05, n = 4 (Figure 3.48).
In order to investigate any effect from nervous system on KC1 responses in isolated 
perfused lungs, prazosin (1 pM), an ai-adrenoceptor antagonist was infused for 15 min 
before bolus-injections of KC1. Prazosin had no effect on the vasoconstrictor responses to 
KC1 in isolated perfused lungs. To confirm that 1 pM prazosin is sufficient to block ai- 
adrenoceptor on the pulmonary vascular smooth muscle, the vasoconstrictor responses to 
PHE were recorded in the absence or presence of prazosin in the isolated perfused lungs, 
prazosin (1 pM) completely abolished the vasoconstrictor responses to PHE in isolated 
perfused lungs (Figure 3.49 & 3.50).
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Figure 3.48: Effect of ET-1 on vasoconstrictor responses to KC1 in normoxic isolated 
perfused lungs.
Data are presented as increases of PPP (mmHg) to bolus injections of KC1 (25 - 400 pmoles) into 
the lungs alone ( D  ) or with ET-1 (InM) (®  ). Each point represents mean ± s. e. mean, n =















Figure 3.49: Effect of a selective ai-adrenoceptor antagonist, prazosin on 
vasoconstrictor responses to KC1 in normoxic isolated perfused lungs.
The vasoconstrictor responses to KC1 (25 - 400 pmoles) were recorded in the absence ( □  ) 
or presence ( of prazosin (1 pM) in normoxic isolated perfused lungs. Each point 
represents mean ± s. e. mean, n = 5 - 6 for each group.
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Figure 3.50: Effect of a selective ai-adrenoceptor antagonist, prazosin on 
vasoconstrictor responses to PHE in normoxic isolated perfused lungs.
The vasoconstrictor responses to PHE (1 - 30 nmoles) were recorded in the absence ( □ >  or
presence ( Q  ) of prazosin (1 pM) in normoxic isolated perfused lungs. Each point represents
mean ± s. e. mean, n = 4 for each group.
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3.3.7 ET-1 sensitization in mesenteric vasculature
For comparison with the results of ET-1 sensitization on vasoconstrictor responses in the 
lungs, responses in the mesenteric bed were also investigated.
Initial experiments were carried out to determine the sub-threshold pressor concentration 
of ET-1 in the isolated perfused mesenteric bed. 0.1 nM or 0.3 nM of ET-1 did not 
change the perfusion pressure significantly, but perfusion pressure significantly increased 
with infusion of 1 nM ET-1; 21.9 ± 1.0 mmHg (n = 4) in the controls vs. 47.9 ±6.8 



















Figure 3.51: Effect of ET-1 on perfusion pressure in isolated mesenteric bed.
The isolated mesenteric bed was perfused without ET-1 ( Q] ) or with 0.1 nM ET-1 ( ^  ), 0.3 nM 
ET-1 ( J  ) or 1 nM ET-1 ( J  ) for 15 min. Each column represents mean ± s. e. mean. *P <
0.05 vs. the controls; one way ANOVA followed by Dunnett’s test, n = 4 for each group.
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Ang II (lpmole -  lOnmoles) produced very poor responses in the isolated perfused 
mesenteric bed. So, only PHE and KC1 were chosen as the vasoconstrictors for study of 
ET-1 sensitization.
The vasoconstrictor responses to 10 nmoles PHE in the isolated perfused mesenteric bed 
were potentiated when infusing the sub-threshold concentration of ET-1 (0.3nM) (66.6 ± 
12.6 mmHg, n = 4), compared with the controls (56.9 ± 12.6 mmHg, n = 4). 10 nmoles 
PHE-induced vasoconstrictor responses were significantly potentiated by infusing the 
threshold concentration of ET-1 (InM) (131.5 ± 12.0 mmHg, n = 4, P < 0.05) (Figure 
3.52).
Similar results were obtained with KC1 (Figure 3.53). The sub-threshold (0.3 nM) or 
threshold (1 nM) vasoconstriction concentration of ET-1 significantly potentiated the 
vasoconstrictor responses to KC1 (50 pmoles) in the perfused mesenteric beds from 
normoxic rats. The increases of mesenteric perfusion pressure induced by 50 pmoles KC1 
were 23.6 ±1.9 mmHg (n = 3) in the controls, 40.0 ±1.3 mmHg with 0.3 nM ET-1 (P < 
0.05, n = 3) and 48.6 ± 2.0 mmHg with 1 nM ET-1 (P < 0.05, n = 3).
136
I  140 '
a>
I  120 ■fa^ iIm
a  100 "_o
C /5  1
<3
fc 80 "a.
E 60 - 
■+■<=s
1 40 -
|  20 -
P
Figure 3.52: Effect of ET-1 on vasoconstrictor responses to PHE in normoxic isolated perfused 
mesenteric bed.
Data are presented as increases of mesenteric perfusion pressure (mmHg) to bolus injections of
) or with 0.1 nM ET-1 ( ^  ), 0.3 nM 
n ± s. e. mean. *P < 0.05 vs. the 
controls; one way ANOVA followed by Dunnett’s test, n = 4 for each group.
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PHE ( 10 nmoles) into the mesenteric artery without ET-1 ( [ 

























Figure 3.53: Effect of ET-1 on vasoconstrictor responses to KC1 in normoxic isolated perfused 
mesenteric bed.
Data are presented as increases of mesenteric perfusion pressure (mmHg) to bolus injections of 
KC1 (50 pmoles) into the mesenteric artery without ET-1 ( Q ] ) or with 0.1 nM ET-1 ( ^  ), 0.3 nM 
ET-1 ( j f | ) or 1 nM ET-1 ( | ) .  Each column represents mean ± s. e. mean. *P < 0.05 vs. the 
controls; one way ANOVA followed by Dunnetf s test, n = 3 for each group.
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3.3.8 Studies in permeabilized pulmonary and mesenteric artery rings
For comparison of the contractile responses between pulmonary and mesenteric arteries, 
pulmonary arteries and mesenteric arteries were set up simultaneously.
Figure 3.54 shows that Ca induced contractile responses m permeabilized pulmonary 
arteries. 0.01 - 10 pM Ca (the concentrations of Ca that had no effect in non- 
permeabilized pulmonary arteries) induced concentration-dependent contractions in the 
permeabilized pulmonary artery rings. This indicated that the vascular smooth muscle in 
the permeabilized pulmonary arteries had been successfully permeabilized. A similar 
result was obtained in permeabilized mesenteric arteries with Ca2+ buffer.
Caffeine (10 mM) induced transient contractile effects in permeabilized mesenteric 
arteries (Figure 3.55). The contractile responses induced by caffeine could be reproduced 
after refilling with 80nM Ca2+/0.2mM EGTA for 10 min after washout. If repeated 
caffeine (10 mM) was applied again without changing the buffer, the response to caffeine 
was abolished. Caffeine (10 mM) induced little contractile response in the permeabilized 















Figure 3.54: [Ca2+]i-tension relationship in a-toxin permeabilized pulmonary and mesenteric 
arteries.
Data are presented as increases of the vascular tension induced by Ca2+ in permeabilized pulmonary 
(A) and mesenteric (B) arteries. Ca2+ was buffered by 10 mM EGTA and 10 mM Ca2+ EGTA. Each 
point represents mean ± s. e. mean, n = 6  for each point in the pulmonary arteries and n = 7 for each 










Figure 3.55: Representative traces illustrating the contractile effect of caffeine in a-toxin 
permeabilized pulmonary and mesenteric arteries.
Bolus-injections of caffeine (10 mM) (code 178, 179, 181 and 183) were added to the permeabilized 
pulmonary (A) and mesenteric (B) arteries. The tissues were washed out with Refilling solution 
(80nM Ca2+/0.2mM EGTA) (code 180 and 182). The responses on code 180 and 182 are artefacts 
from washout.
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3.4 Effect of CH on catecholamine metabolism in isolated lungs 
3.4.1 Catecholamine removal in CH isolated lungs
Removal of NA and Adr was estimated by bio-assay of the fraction surviving passage 
through the lung. NA removal was 49.7 ± 9.9 % (n = 6 ) in normoxic lungs vs. 47.9 ± 
8.2% (n = 6 ) in CH lungs, P > 0.05. Adr removal was significantly lower than NA 
removal in normoxic lungs, 29.2 ± 5.8%, n = 8  (P < 0.05). However CH increased Adr 
removal to 46 ± 6 .6 %, (n = 8 ), significantly higher than Adr removal in normoxic lungs, 
P < 0.05 (Figure 3.56).
For comparison, 5-HT removal was dertermined. 5-HT was almost completely removed 
from normoxic isolated perfused lungs (82.5 ± 2.8 %, n = 6 ). CH had no significant effect 
on this removal (69.8 ± 7.0 %, n = 6 ), P > 0.05 (Figure 3.57).
Further experiments were carried out to determine the mechanism of Adr removal in CH 
lungs, using Uptakei and Uptake inhibitors. The inhibitors were infused through the 
isolated perfused lungs for 15 min before infusion of Adr. The removal of Adr in CH 
lungs did not change in the presence of corticosterone (10 pM), an Uptake inhibitor (46 
± 11.3%, n = 4, P > 0.05), when compared with CH controls. However cocaine (1 pM), 
an Uptakei inhibitor reduced the removal of Adr in CH lungs (6 . 6  ± 4.8%, n = 5), 



















Figure 3.56: NA and Adr removal in normoxic and CH isolated perfused lungs.
NA and Adr removals were measured in the normoxic ( Q j ) or CH ( rat lungs. Each column 
represents mean ± s. e. mean. * P < 0.05 vs. the controls; unpaired Student’s t-test. n = 6  for each 
group in NA removals and n = 8  for each group in Adr removals.
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Figure 3.57: 5-HT removal from normoxic and CH isolated perfused lungs.
5-HT removals were measured in the normoxic ( Q ) or CH ) rat lungs. Each column 
represents mean ± s. e. mean, n = 6  for each group.
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Figure 3.58: Effect of Uptake inhibitors on Adr removal in CH isolated perfused lungs.
Adr removal was measured in CH lungs in the absence of any inhibitor ( J ) or presence of 
corticosterone (10 pM), Uptake2 inhibitor ( J ||) or cocaine (1 pM), Uptakei inhibitor ( ^ ) .  Each 
column represents mean ± s. e. mean. *** P < 0.001 vs. CH controls; unpaired Student’s t-test. n = 8 
for CH controls, n = 4 for corticosterone treated group and n = 5 for cocaine treated group.
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3.4.2 Effects of pulmonary oedema and low oxygen perfusion on Adr removal in
isolated lungs
Normally, the isolated perfused lungs were stable over 3 hours. After 3 hours, lung 
weight increases as pulmonary oedema appears. Adr removal was also checked after lung 
weight had increased over 30%; lung weights were 2.5 ± 0.3g in the controls vs. 3.9 ± 
0.5g in the oedematous lungs. The pulmonary oedema produced in normoxic lungs did 
not change Adr removal (26 ± 7.3%) when compared to the controls (29 ± 8.1% n = 5, P 
> 0.05) (Figure 3.59).
When the perfusate solution was aerated by 10% O2 mixture, Adr removal in CH lungs 
(38 ± 6 .8 %, n = 7) was still similar to Adr removal in CH controls (46 ± 6 .6 %, n = 8 , P > 
0.05) (Figure 3.60).
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Figure 3.59: Effect of pulmonary oedema on Adr removal in normoxic isolated perfused 
lungs.
Adr removal was measured in the normoxic lungs ( Q  ) or the lungs with oedema ( ^  ). Each 
column represents mean ± s. e. mean, n = 5 for each group.
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Figure 3.60: Effect of hypoxic perfusion on Adr removal in CH isolated perfused lungs.
Adr removal in CH lungs was not statistically different after switching on 10% 0 2 ( gy ) from 20% 
0 2 ( | ) m  the perfusate buffer. The Krebs’ solution was bubbled with 10% 0 2 or 20% 0 2 for 30 
min before experimental recording. Each column represents mean ± s. e. mean, n = 7 for 20% 0 2 





4.1 Pulmonary vascular hyper-reactivity in isolated lungs of CH rats
CH-induced pulmonary hypertension occurs in residents at high altitude and in chronic lung 
diseases (Peacock & Raeside, 1998; Rostrup, 1998). Pulmonary hypertension was found 50 
years ago, but still attracts many scientists to study it, because the exact mechanism is 
unknown. In our animal model, rats exposed to hypoxia for 3 weeks showed higher 
haematocrits and higher pulmonary pressures than in the controls in vitro. The ratio of right 
ventricular weight to total ventricular weight, which was chosen as an index of right 
ventricular hypertrophy, was also higher in CH rats compared to the normoxic rats. These 
data confirm the presence of pulmonary hypertension in the CH rats and associated 
cardiovascular changes similar to those seen in humans.
Exposure to CH potentiated the vasoconstrictor responses to all agonists tested (PHE, 
Ang II, KC1, U46619, and NA) in the isolated perfused lungs, even though these agonists 
act through different receptors on the vascular smooth muscle cells. KC1, which acts via
I
membrane depolarization induced Ca influx into vascular smooth muscle cells (Ko et 
al., 1997), also produced potentiated vasoconstrictor responses in CH isolated lungs. The 
vasoconstrictor responses to PHE or NA were potentiated in CH lungs starting from the 
threshold doses. The threshold dose-responses to other agonists (Ang II, KC1 and 
U46619) were the same in CH and the control groups; the responses to those agonists 
were potentiated at higher doses in CH lungs. However, ED5 0S of all agonists in CH rats 
were similar to the controls. It is thus unlikely that the changes of responses in CH are 
caused solely by an increase in receptor number for two reasons: 1) KC1 is a non-receptor 
mediated agonist; 2) the increases to Ang II were not parallel shifted to the left.
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Previous work has shown that normoxic perfusion (2 0 %O2) of CH lungs increased the 
basal PPP via increased ET synthesis, but hypoxic perfusion (0% O2) did not change 
basal PPP (Lai et a l , 1999b). In order to investigate whether normoxic perfusion affected 
pulmonary vasoconstrictor responses in CH lungs, different oxygen concentrations were 
applied in the perfusate into isolated CH lungs. There was no difference of pulmonary 
vasoconstrictor responses to PHE between normoxic perfusion (2 0 %C>2) and hypoxic 
perfusion (1 0 %O2). This suggests that oxygenation of the perfusate is not the reason for 
the potentiation of vasoconstrictor responses in CH lungs.
In contrast to pulmonary vasculature, there are no potentiated contractile responses to PHE in 
aortic rings from CH rats as shown in this study. In uterine artery, a decrease of contractile 
responses to NA was observed in the CH animals (Hu et a l, 1999). Thus, it appears that 
vascular hyper-reactivity is specific for pulmonary circulation during CH and that the 
mechanism involved is at a common point in the contractile process.
Enhanced vasoconstrictor responses to Ang II in CH rat lungs have been also reported by 
other groups (Emery et al., 1981; Jin et a l, 1987). ET-1, another important 
vasoconstrictor for pulmonary vasculature also induced potentiated vasoconstrictor 
responses in isolated CH lungs (Lai et a l, 2000). Monocrotaline-induced pulmonary 
hypertension exhibited the enhanced vasoconstrictor responses in the pulmonary 
circulation (Gillespie et a l, 1986).
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4.2 ET-1 sensitization on vasoconstrictor responses in normoxic isolated lungs
ET-1 as a potent vasoconstrictor is strongly indicated in hypoxic pulmonary 
hypertension. Hypoxia up-regulates ET converting enzyme activity and induces 
production of ET-1 (Lai et al., 2000). Also, the number of ETa receptors in the media of 
pulmonary resistance arteries increases (Soma et al., 1999). Furthermore, BQ123, a 
selective ETa receptor antagonist, attenuated the development of hypoxic pulmonary 
hypertension in rats in vivo, suggesting the involvement of ETs (Bonvallet et al., 1994).
Hence, the potentiated vasoconstrictor responses to agonists in CH lungs observed in the 
present study might be due to increased production of endogenous ET-1 during CH. 
Thus, the effects of ET-1 on vasoconstrictor responses in normoxic lungs were carried 
out to try to mimic the pulmonary hyper-reactivity seen in isolated perfused lungs of CH 
rats.
Although the plasma concentration of ET-1 is increased in pulmonary hypertension 
(Stewart et al., 1991; Yoshibayashi et a l , 1991), it is still not sufficient to induce direct 
constriction of pulmonary arteries. Therefore, the concentration of ET-1 utilised for these 
sensitization studies was deliberately selected as sub-threshold, as determined by 
measurement of perfusion pressure.
The preliminary experiments were carried out to define this sub-threshold concentration 
of ET-1. It was found to be InM ET-1 in the isolated perfused lung preparation and 0.3
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nM ET-1 in isolated perfused mesenteric bed. The threshold concentration of ET-1 do not 
significantly increase [Ca2+]i as demonstrated in porcine coronary artery (Nakayama et 
a l , 1991).
Duration of ET-1 infusion was found to be important in sensitization to vasoconstrictors 
in the perfused lung. The time course of sensitization by ET-1 was measured in this 
study. Infusion of InM ET-1 for 30, 45 or 60 minutes significantly potentiated the 
vasoconstrictor responses to Ang II, and a 30 minutes infusion was chosen as the 
optimum.
ET-1 infused for 30 minutes potentiated the vasoconstrictor responses to PHE and Ang II 
in normoxic isolated perfused lungs. Low concentrations of ET-1 can also potentiate the 
vasoconstrictor responses to NA but not U46619, a TxA2 mimetic, in porcine aortae, 
(Scotland et al., 1999). That is because ET-1 shares a common signalling pathway with 
other vasoactive hormones, such as Ang II, NA and vasopressin in the vascular smooth 
muscle contraction (Marsden et al., 1989). Furthermore, other agonists whose receptors 
are G-protein coupled can mutually amplify their vasoconstrictor responses, e.g. oti- 
adrenoceptor agonists and 5 -HT2 receptor agonists (Christ et al., 1990).
In the present study, ET-1 significantly potentiated the vasoconstrictor responses to PHE 
and Ang II in the isolated perfused lung, even though the changes were not dramatic. The 
explanation is that changes of [Ca ]j plays a key role in vascular smooth muscle
• 9+  • •contraction rather than Ca sensitization. Another reason may be because infusion of
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ET-1 into lungs not only stimulates ETa and ETb2 receptors on the vascular smooth 
muscle cells; but also stimulates ETbi receptors inducing NO and PGI2 release from 
vascular endothelial cells. This has been shown using L-NOARG, a NO synthase 
inhibitor plus indomethacin, a cycloxygenase inhibitor, which completely abolished the 
vasodilation responses induced by ET-1 in isolated perfused lungs (Lai et al., 1996). 
Generation of such potent vasodilators could attenuate the potentiation effect of ET-1 on 
the vasoconstrictor responses to agonists. The effects of these antagonists on ET-1 
sensitization were not studied.
High K+-mediated contraction in vascular smooth muscle cells is thought to be through
 ^1  ^ I
depolarization of membrane potential and an increase of Ca influx through L-type Ca 
channels (Zhang & Xiao, 1998). However, it is still possible that high K+ might stimulate 
sympathetic nerve terminals in the lung to release NA which would induce 
vasoconstriction through ai-adrenoceptors on pulmonary vascular smooth muscle cells. 
To investigate this possibility, the effect of the ai-adrenoceptor antagonist prazosin on 
the vasoconstrictor responses to high K+ (25 - 400 pmoles KC1) was tested in normoxic 
lungs. In the presence of prazosin the vasoconstrictor responses to PHE were completely 
abolished, indicating effective ai-adrenoceptor blockade; in contrast, the vasoconstrictor 
responses to high K+ did not change. Thus NA release from sympathetic nerve terminals 
does not contribute to the vasoconstrictor responses induced by high K+.
It is intriguing that the sub-threshold concentration of ET-1 did not potentiate 
vasoconstrictor responses to high K+ in normoxic isolated lungs. The main difference
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between membrane depolarization induced by high K+ and agonist-induced activation 
appears to be related to the activation of membrane bound enzymes, which are stimulated 
by the latter but not the former. The consequences of this appear to be twofold: 1) 
agonist-induced Ca2+ influx is more effective in raising [Ca2+]i than Ca2+ influx induced 
by membrane depolarization only (Karaki et al., 1997); 2) agonists enhance the
9+sensitivity of the myofilaments to Ca , whereas this probably does not occur if the 
smooth muscle cells are activated solely by membrane depolarization (Nishimura et al., 
1989). In contrast to the vasoconstrictor responses to high K+ with ET-1 in normoxic 
lungs, the vasoconstrictor responses to high K+ were potentiated in CH isolated lungs 
described previously in this study. So these different results indicate that the pulmonary 
vascular hyper-reactivity exhibited in CH lungs may not involve ET-1 sensitization to 
vasoconstrictor responses in pulmonary vasculature.
In order to compare the sensitizing effect of ET-1 in different vasculature, the 
vasoconstrictor responses to PHE and high K+ were investigated in the normoxic isolated 
perfused mesenteric bed. In this tissue, vasoconstrictor responses to high K+ were 
significantly potentiated by sub-threshold (0.3 nM) or threshold (InM) concentrations of 
ET-1.
The explanation for the difference of high K+-induced vasoconstrictor responses with ET- 
1 between the isolated lung and mesenteric bed can be found from the study of Ca2+ 
mobilization in the permeabilized vessels. Caffeine, an opener of CICR ryanodine- 
sensitive channels (Nishimura et al., 1989; Lagaud et al., 1999), induced contractile
155
responses in permeabilized mesenteric artery rings, demonstrating the existence of CICR 
in the rat mesenteric vascular smooth muscle cells. However, in the permeabilized 
pulmonary artery rings caffeine induced little or no contractile response. Similar results 
were obtained from measurement of [Ca2+]i. Caffeine (30mM) did not change [Ca2+]j in 
the cultured canine pulmonary vascular smooth muscle cells (Shimoda et al., 2000). 
Pretreatment with ryanodine, an inhibitor of caffeine-sensitive Ca2+ release from SR, had
9-4-no significant effect on the Ca increases induced by KC1, PHE or ET-1 in isolated rat 
pulmonary smooth muscle cells. However thapsigargin, a Ca2+-ATPase inhibitor which 
blocks the SR Ca2+-ATPase and thus can deplete all Ca2+ stores in SR (Maxwell et a l , 
1998; Ivery et a l , 1999), abolished Ca2+ mobilization induced by PHE in the same 
preparation (Hamada et a l, 1997).
Generally speaking, Ca2+ release from SR in vascular smooth muscle cells is through 
ryanodine and IP3 receptors on SR. However, distributions of ryanodine and IP3 receptors 
are tissue-dependent. For example, in cardiac myocytes, CICR plays a central role in 
cardiac excitation-contraction coupling, but not DVinduced Ca2+ release. Both 
ryanodine- and HVreceptors are ivolved in Ca2+ release from SR in mesenteric and aortic 
smooth muscles (Ito et a l, 1986; Lagaud et a l, 1999). In pulmonary vascular smooth
9-4- __muscle cells, Ca release from SR is through IP3 receptors rather than ryanodine 
receptors.
Taken together, these results suggest that high K+ does not cause CICR in pulmonary 
smooth muscle cells of rats and ryanodine receptors may not exist in them. The
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differential distribution of ryanodine receptors could be one factor for the differential 
effect of ET-1 on K+-induced vasoconstrictor responses in the pulmonary and mesenteric 
vasculature. Further studies are required to investigate in more detail differentiation in 
Ca mobilization between pulmonary artery and systemic resistance vessels.
To determine which ET receptors were involved in the potentiation effect of ET-1 on 
vasoconstrictor responses in normoxic lungs, the selective ETa receptor antagonist, PD 
156707 (Maguire & Davenport, 1995; Reynolds et a l , 1995) and the selective ETb 
receptor antagonist, BQ788 (Ishikawa et a l , 1994; Webb & Meek, 1997) were used. Both 
PD156707 and BQ788 blocked the potentiating effect of ET-1 on the vasoconstrictor 
responses to PHE and ANG II, respectively, demonstrating that both ETA and ETb 
receptors are involved in ET-1 sensitization.
ET receptor sub-types, which mediate ET-1-induced vasoconstriction, vary between 
species and vascular beds. For example, ET-1 potentiates the pressor responses to NA in 
perfused rat mesenteric arteries mainly through ETb receptors (Kita et a l, 1998). ETA 
receptors are dominant in human pulmonary artery, whereas ETb receptors are dominant 
in rabbit pulmonary artery (Fukuroda et a l, 1994). In the pulmonary artery tree, the 
distribution of ET receptor sub-types is regionally different. In rat large extrapulmonary 
arteries, only ETA receptors are involved in vasoconstrictor responses to ET-1; in 
contrast, in intrapulmonary resistance arteries ETb receptors mediate vasoconstrictor 
responses to ET-1 (MacLean et a l , 1994b; MacLean et a l, 1995; Soma et a l, 1999). In 
rat pulmonary artery rings, Evans et a l  (1999) found that ET-1 induced an increase in
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myofilament sensitivity to Ca2+ through ETa receptors, but not ETb receptors. This is not 
surprising as the pulmonary arterial rings selected for their experiments had no ETb 
receptors (demonstrated by the fact that SX6 C, a selective ETb agonist, did not induce 
vasoconstrictor responses). It is not difficult to understand that ET-1 sensitizes pulmonary 
vascular smooth muscle via actions on both ETa and ETB receptors in the lungs, as the 
entire vascular bed is perfused.
Further investigation was carried out into the intracellular signalling pathway, which may 
be involved in ET-1 sensitization of vasoconstrictor responses. ET-1 activates multiple 
signalling systems in vascular smooth muscle, including phospholipase C, phospholipase 
D, phospholipase A2, tyrosine kinases and PKC, as demonstrated in the mesenteric artery 
(Ohanian et al., 1997). In the canine pulmonary circulation, ET-1 caused pulmonary 
vasoconstriction through PKC activation (Barman & Pauly, 1995). In cultured rat aortic 
smooth muscle cells, ET-1 stimulates PKC through DAG (Griendling et al., 1989). In 
aortic rings, NA-induced contraction was potentiated by ET-1 in the absence of changes 
in stimulated Ca2+ entry, and the PKC inhibitors, staurosporine and calphostin, prevented 
the potentiation effect of ET-1 (Henrion & Laher, 1993). PKC is considered to inhibit 
myosin light chain phosphatase and to make smooth muscle cells more sensitive to Ca2+ 
(Nishimura et al., 1989; Weissman et al., 1999). Thus, PKC might be a candidate for 
myofilamental sensitisation by ET-1 in the isolated lung.
PKC inhibitors were used to investigate the role of PKC in ET-1 in the present study. Ro- 
32-0432, a selective PKC inhibitor (Birchall et al., 1994; Huang et a l, 2000), did not
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alter the potentiated vasoconstrictor responses to Ang II by ET-1. Staurosporine inhibited 
the vasoconstrictor responses to Ang II with ET-1. In fact, the vasoconstrictor responses 
to Ang II in the presence of ET-1 plus staurosporine were lower than the control group. 
However, staurosporine is a non-selective kinase inhibitor and can also affect PKA, PKG 
and myosin light chain kinase (Ivery et a l, 1999). PKC involvement in the sensitizing 
action of ET-1 concluded by other groups is probably because they used such non- 
selective inhibitors, like H-7 and staurosporine (Nishimura et a l , 1992; Wilkinson & 
Hallam, 1994; Webb & Meek, 1997). The present studies indicate that ET-1 sensitization 
of the pulmonary artery in the rat lungs is not related to PKC activation.
pHi is another important factor in vascular smooth muscle cells which can modulate 
vascular tone (Krampetz & Rhoades, 1991). Increase or decrease of pHi in vascular 
smooth muscle cells would, respectively, potentiate and blunt vasoconstrictor reactivity
j  I
by changing Ca sensitivity in the cells (Raffestin & McMurtry, 1987). pHi can be 
changed via extracellular pH or the action of agonists (Smith et a l, 1998). The Na+/H+ 
exchanger plays an important role in controlling pHi by exchanging intracellular H+ for 
extracellular Na+. The resultant intracellular alkalinization enhances Ca2+ sensitivity to 
vasoconstrictors. In rabbit cardiomyocytes, contraction induced by ET-1 was inhibited by 
HOE642, a selective Na+/H+ exchanger inhibitor, without a significant effect on [Ca2+]i 
(Wang et al., 2000). This proves that ET-1 does increase Ca2+ sensitivity via the Na+/H+ 
exchanger. However, HOE642 failed to inhibit the potentiation effect of ET-1 on the 
vasoconstrictor responses to Ang II in normoxic isolated perfused lungs in this study. A 
Na+/H+ exchanger does exist in pulmonary arterial smooth muscle cells demonstrated in
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guinea pig and ferret and cat (Quinn et al., 1991; Farrukh et al., 1996; Madden et al., 
2001). Furthermore, it has been demonstrated that Na+/H+ exchanger is present in both 
large and small pulmonary arteries and plays an important role in the regulation of pHi in 
the pulmonary circulation (Madden et al., 2001). However, ET-1 sensitization in the 
pulmonary circulation does not appear to involve the Na+/H+ exchanger and regulation of 
pHi.
Tyrosine kinase is also not involved in ET-1 sensitization in rat permeabilized pulmonary 
arterial rings, as demonstrated by Evans et al. (1999).
Vascular smooth muscle contraction depends on myosin light chain phosphorylation in 
the cells. The activities of myosin light chain kinase and myosin light chain phosphatase 
decide the extent of myosin light chain phosphorylation. Myosin light chain kinase 
activity depends on [Ca ]j. In contrast, inhibition of myosin light chain phosphatase, 
which decreases the dephosphorylation of phosphorylated myosin light chain, can 
indirectly increase the phosphorylation of myosin light chain and does not depend on 
[Ca2+]. Rho-kinase phosphorylates myosin light chain phosphatase and therefore inhibits 
its activity (Weissmann et al., 1999). Robertson et al. (2000) have demonstrated that Y- 
27632, a specific inhibitor of Rho-activated kinase, prevented HPV in isolated 
intrapulmonary artery rings and isolated perfused lungs from rats (Robertson et al., 
2000). This indicates that increased Ca sensitivity plays a role in HPV. Therefore, Rho- 
kinase could be a candidate for ET-1 sensitization of vasoconstrictor responses in the 
isolated perfused lung.
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4.3 Effect of inhibitors of ET-1 synthesis on pulmonary vascular hyper-reactivity in
CH isolated lungs
To elucidate whether endogenous ET-1 is responsible for pulmonary vascular hyper­
reactivity in CH lungs, ET receptor antagonists and an ET converting enzyme inhibitor 
were used.
As the ai-adrenoceptor is an important receptor in the regulation of pulmonary tone 
(Salvi, 1999), PHE, an ai-adrenoceptor agonist was chosen first. PD 156707 (5 pM), 
another selective ETa receptor antagonist did not alter the vasoconstrictor responses to 
PHE in CH isolated perfused lungs. Experiments had shown that vasoconstrictor 
responses to ET-1 were effectively blocked in normoxic isolated perfused lungs, 
indicating that the concentration of PD 156707 was sufficient to block ETA receptors. 
BQ788, a selective ETb receptor antagonist, also had no effect on the vasoconstrictor 
responses to PHE in CH lungs.
Conversion of big ET-1 to mature ET-1 is essential for the expression of full biological 
activity of ET-1 (Hisaki et a l , 1994). Phosphoramidon, an ET converting enzyme 
inhibitor prevents the conversion of big ET-1 into ET-1 (Hisaki et al., 1994; Held et a l ,
1997). However, phosphoramidon (10 pM) (Smith et a l, 1997) had no effect on the 
vasoconstrictor responses to PHE.
BQ123 however had no effect on the vasoconstrictor responses to Ang II or KC1 in CH
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lungs. The vasoconstrictor responses to KC1 in CH lungs were also not affected by 
BQ788.
Accordingly, these studies do not support the hypothesis that endogenous ET-1 
production plays a role in pulmonary vascular hyper-reactivity during CH.
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4.4 Relationship between pulmonary vascular remodelling and pulmonary vascular
hyper-reacitivity induced by CH
Pulmonary vasculature shows pulmonary vasoconstriction during the early stage of 
hypoxic pulmonary hypertension, and is gradually supplanted by progressive structural 
changes, so called ‘muscularization’ of pulmonary arteries (Meyrick & Perkett, 1989). 
This new muscle encroaches on the vascular lumen and makes it narrow. This increase in 
vascular smooth muscle has been cited as the reason for the augmentation of 
vasoconstrictor responses to different agonists in CH lungs (Emery et al., 1981).
An approach was designed to determine whether the increased vascular reactivity in CH 
lungs is due to ‘muscularization’. This involved measuring the time-course of onset and 
offset of vascular hypertrophy during and after CH and measuring changes in vascular 
reactivity at these times.
After 21 days hypoxia the vasoconstrictor responses to PHE, Ang II and KC1 were all 
significantly potentiated. The time course of onset of these effects appeared to be similar 
for each of the agonists. This would support a correlation between pulmonary hyper­
reactivity and ‘muscularization’. However discrepancies were noted in these two 
parameters when animals were returned to normoxic conditions (recovery). The 
vasoconstrictor responses to PHE in the isolated perfused lungs returned to control levels 
after 21 days recovery. However, the vasoconstrictor responses to Ang II and KC1 in the 
isolated lungs were still augmented after 2 1  days recovery.
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Extensive histological examination of pulmonary arteries was carried out in lungs taken 
after 2 1  days hypoxia and 2 1  days recovery and compared with the age-matched controls. 
The ratio of pulmonary wall thickness was significantly higher after 21 days hypoxia, 
compared to normoxic vessels. This hypertrophy was still present after 21 days recovery.
Right ventricular hypertrophy is a well-established index for the degree of pulmonary 
hypertension, because a close correlation between wall thickness of small arteries and the 
degree of right ventricular hypertrophy has been noticed (Hislop & Reid, 1976). Ratios of 
right ventricular to total ventricular weight were significantly increased after 2 1  days 
hypoxia and were still significantly higher than control after 21 days recovery. This data 
suggests that regression of pulmonary vascular remodelling and right ventricular 
hypertrophy takes place over a much longer period, more than 2 1  days after animals 
transferred from 2 1  days hypoxic condition to normoxia in this study.
It would appear that pulmonary vascular remodelling correlates well with the 
vasoconstrictor responses to Ang II and KC1. However, PHE-induced vasoconstrictor 
responses regress more rapidly than vascular hypertrophy. This suggests a different 
mechanism is involved in the potentiation of PHE responses. The density of cxi- 
adrenoceptor was up-regulated in pulmonary artery during hypoxia (Xie et a l , 1991); and 
the responses to PHE and NA were shifted to the left in the isolated lungs during CH, 
described before. Thus, an increase of a-adrenoceptor number could be involved in the 
potentiation of vasoconstrictor responses to a-adrenoceptor agonists during CH.
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Results from a different study also suggest that pulmonary vascular remodelling in CH 
lungs does not parallel the alteration of pulmonary vascular function. When pulmonary 
vascular remodelling in CH was attenuated by an angiotensin converting enzyme 
inhibitor, perindopril, the potentiated vasoconstrictor responses to 5-HT or U46619 still 
persisted in pulmonary artery rings (Jeffery & Wanstall, 1999). This suggests that the 
proliferation of vascular smooth muscle alone cannot account for the pulmonary vascular 
hyper-reactivity in hypoxic pulmonary hypertension.
Apart from muscularization, another possible factor on pulmonary vascular hyper­
reactivity during CH is membrane potential of pulmonary artery smooth muscle cells. In 
adult pulmonary artery smooth muscle cells, K+ channels determine the membrane 
potential and both acute and chronic exposures to hypoxia cause K+ channel inhibition 
and then membrane depolarisation (Archer et al., 1998). The membrane depolarisation 
brings the membrane potential closer to the threshold for activation of L-type Ca2+ 
channels (Yuan et al, 1990; Evans et al, 1998). Therefore, vasoconstrictors, e.g. PHE, 
Ang II and KC1 could induce extracellular Ca2+ influx more easily during CH.
In order to obtain more detailed knowledge of the mechanisms underlying the potentiated 
responses in CH lungs, studies were undertaken using rings of pulmonary artery from the 
different regions of pulmonary artery tree. The physiological and pharmacological 
characteristics of large and small pulmonary arteries are heterogeneous. Morphological 
studies also have shown that the structures in the wall of pulmonary conduit arteries are
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different from those in the wall of pulmonary muscular arteries (Sasaki et a l, 1995). 
There is great heterogeneity in the phenotype of the vascular smooth muscle cells in 
pulmonary artery tree. K+ channels are one example of the discrepant distributions in the 
pulmonary artery tree (Post et al., 1992; Albarwani et al., 1995). The heterogeneity in 
distribution of K+ channels may explain some of the discrepancies in vascular reactivity 
noted between pulmonary resistance and conduit arteries in response to hypoxia. 
Pulmonary resistance arteries respond to hypoxia by inhibition of whole cell K+ current 
and depolarisation of the membrane leading to Ca2+ influx and the vascular smooth 
muscle constriction (Albarwani et al., 1995). Pulmonary conduit arteries are more akin to 
systemic arteries and respond to hypoxia by potentiation of K+ current and 
hyperpolarisation of the membrane and therefore the vascular smooth muscle relaxation 
(Albarwani et al., 1995). That is because pulmonary resistance artery smooth muscle 
cells have a higher density of Kv channels, which exhibit oxygen sensitivity by their K+ 
channel inhibition (Post et al, 1992). Conversely, in pulmonary conduit arteries there is a 
higher proportion of Kca channels, which increase whole cell K+ current during hypoxic 
exposure. Conduit and resistance pulmonary myocytes also differ in their voltage gated 
(L-type) Ca channel response to hypoxia. In the conduit arteries hypoxia inhibits Ca 
current whereas in resistance arteries hypoxia increases Ca2+ influx (Brij & Peacock,
1998).
For comparison between large and small pulmonary arteries, all vasoconstrictor 
responses induced in pulmonary arterial rings were standardized by the contractile 
responses to 50 mM KC1 in the same preparation. This kind of standardization allows
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comparison of the vasoconstrictor responses to the same agonist in different sizes of 
vessel. After standardization, concentration-dependent contractions to KC1 were exactly 
the same in large and small pulmonary artery rings. Vasoconstrictor responses to Ang II 
were also similar between the two groups, even though the responses to Ang II in the 
small pulmonary artery rings were slightly smaller. In contrast, the vasoconstrictor 
responses to PHE were much smaller in the small pulmonary arteries than in the large 
pulmonary arteries.
Previous studies have also demonstrated that the vascular reactivity to vasoconstrictors is 
not uniform along the pulmonary vasculature (Lai et al., 1999a). ai-Adrenoreceptors are 
expressed on most vascular smooth muscle cells, and their sub-types are distributed in a 
pattern that is specific for functionally distinct vessel types. The population of these 
receptors and their sub-types vary greatly, not only in different vessels but also at 
different levels within the same vascular tree, thereby exhibiting regional variations in 
their reactivity to various agonists (Salvi, 1999). Therefore, different receptor 
distributions and/or different intrinsic contractility between the large and small 
pulmonary arteries might be the reason for the regional variations of the vasoconstrictor 
responses in the pulmonary artery rings shown in this study.
During CH, the vasoconstrictor responses to 5-HT were significantly increased in the 
pulmonary resistance artery rings, compared to the controls, whereas the responses to 
KC1 and PHE were unchanged and Ang II-induced responses were reduced in the 
pulmonary resistance arteries from CH rats. For ET-1, there is an increase in the
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vasoconstrictor responses to ET-1 in the small muscular pulmonary arteries in CH rats. In 
the large elastic arteries of CH rats, depending on experimental conditions, both increases 
and decreases in responsiveness to ET-1 have been reported (Bialecki et al., 1998). 
Previous work in our laboratory has reported that in pulmonary artery rings, CH enhanced the 
vasoconstrictor responses to PHE (Lai et al., 1999a). However, there were no enhanced 
responses to Ang II or ET-1 in main pulmonary rings from CH rats (MacLean et a l , 
1995; Jeffery & Wanstall, 1999; Lai et al., 1999a). Pulmonary arterial responses to 5-HT 
are markedly enhanced at all levels of the pulmonary arterial circulation from CH rats 
(MacLean, 1999a). In extralobar pulmonary arterial rings, decreases in pulmonary 
vasoconstrictor responses to ET-1, BaCH or KC1 were reported in CH rats compared with 
the controls (Bialecki et al., 1998). However Maclean et al. (1995) reported that in 
extralobar pulmonary arteries from rats with 14 days CH, sensitivity to ET-1 was 
increased. The pulmonary vessel rings showed discrepancy of vasoconstrictor responses 
to different agonists during CH. Again, these results suggests that pulmonary vascular 
hyper-reactivity during pulmonary hypertension is not simply because of pulmonary 
muscularization.
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4.5 Effect of CH on metabolism of catecholamines in isolated lungs
Exposure to hypoxia stimulates sympathetic activity and increases circulating 
catecholamine levels (Morgan et al., 1995; Heindl et al., 2001). The enhanced vascular 
reactivity to adrenoceptor agonists, PHE and NA in CH lungs, described before could be 
due to changes in the number of adrenoceptors or changes in metabolism of 
catecholamines during CH. So, it was of interest to study the metabolism of 
catecholamines during CH.
The lung is an important organ which inactivates many biological substances in plasma, 
for example catecholamines, 5-HT, ET-1 etc. (Vane, 1969; Bryan-Lluka et al., 1992a). 
So, isolated perfused lungs were used for investigation of catecholamine removal. Similar 
to other reports (Bakhle & Vane, 1974), this study has shown that the lungs removed 
almost all 5-HT (82 %) in normoxic rats. NA removal was higher than Adr removal in 
normoxic lungs. The differential removal of catecholamines in the lungs has been 
observed by others (Bryan-Lluka & O'Donnell, 1992b). The explanation for this 
phenomenon could be due to the different affinities of uptakei and uptake2 for Adr and 
NA (Trendelenburg, 1991).
Interestingly, CH increased the Adr removal in the lungs, but did not change NA or 5- 
HT removal. The increase of catecholamine removal is explained as increased 
sympathetic nerve activity during hypoxia, the increase of catecholamine removal that 
attenuates the rise of plasma concentration of catecholamine.
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A previous study has shown that normoxic perfusion (20% O2) of CH lungs increased 
basal PPP, whereas hypoxic perfusion of CH lungs caused no change (Lai et al., 1999b). 
In order to see any effect of changes in oxygen concentration on catecholamine removal, 
CH lungs were perfused with Krebs’ solution gassed by different oxygen concentrations. 
Results showed that there was no difference in Adr removal in CH lungs when perfused 
with normoxic (20%) and hypoxic (10%) mixture.
In normoxic lungs the removal of catecholamine occurs by Uptake 1 rather than Uptake2 
(Alabaster & Bakle, 1973; Bryan-Lluka et a l , 1992b). During CH corticosterone, an 
Uptake2 inhibitor, had no effect on the removal of Adr in CH lungs. However, cocaine, 
an Uptakei inhibitor, reduced Adr removal. This suggests that the uptake mechanism of 
catecholamines during CH is the same as normoxia. Although early reports have shown 
that pulmonary catecholamine uptake occurs by a transporter with the properties of both 
extraneuronal Uptake2 and neuronal Uptakei, it was found that in intact perfused lungs of 
rats that the transporter in the pulmonary endothelial cells has the same properties as the 
neuronal NA transporter, Uptakei (Porzgen et al., 1998).
When comparing uptake of Adr in the absence and presence of an inhibitor, the later 
measurements were, of necessity carried out at a later time in the experiment and lung 
weight has started to increase. Thus Adr uptake in lungs with marked pulmonary oedema 
was compared to normal lungs. Pulmonary oedema did not affect Adr removal.
170
The possibility exists that the increased Adr uptake into the walls of the pulmonary blood 
vessels, coupled with increased plasma concentrations in CH (Morgan et al., 1995) would 
cause vasoconstriction. This together with increased vascular reactivity could contribute 
to pulmonary hypertension seen in CH. The enhanced vascular reactivity appears to occur 
at a late stage, probably via sensitization of the myofilaments to Ca2+, possibly via rho 
kinase. Although ET synthesis is increased in CH lungs and can sensitize pulmonary 
blood vessels, its role in the vascular hyper-reactivity seen in CH remains equivocal.
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4.6 Conclusions
CH induces pulmonary vascular hyper-reactivity, which was demonstrated in the isolated 
perfused lungs from CH rats, using various vasoconstrictors (PHE, KC1, Ang II, NA, 
U46619). However, the agonists had discrepant vasoconstrictor responses in the 
pulmonary resistance arteries from CH rats.
Although it is demonstrated that ET-1 can potentiate the vasoconstrictor (PHE and Ang 
II) responses via both ETa and ETb receptors in the lungs from normoxic rats, ET 
receptor antagonists and ET converting enzyme had no effect on the potentiation of 
vasoconstrictor responses in CH lungs. These results do not suggest a role of endogenous 
ET in pulmonary vascular hyper-reactivity during CH.
From the time-dependent studies of vasconstrictor responses and pulmonary vascular 
remodelling, the pulmonary vascular remodelling can partly explain the mechanism of 
pulmonary vascular hyper-reactivity because the time course of the enhanced 
vasoconstrictor responses to Ang II and KC1 was correlated with the time course of 
pulmonary vascular remodelling during hypoxia and recovery. However, the onset and 
offset of CH on the vasoconstrictor responses to PHE was different from the responses to 
Ang II and KC1 and did not parallel the process of pulmonary vascular remodelling under 
the impact of hypoxia and normoxia. It appears some other factors are involved in PHE- 
induced vasoconstrictor responses in CH lungs.
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4.7 Future work
1. Investigation of the distribution of a-adrenoceptors in pulmonary arterial tree in 
normoxic and CH rats.
2. Investigation of a Rho-kinase inhibitor (e. g. Y27632) on ET-1 sensitization in 
permeabilized pulmonary artery rings.
3. Quantified measurement of caffeine-induced contraction in the permeabilized vessels 
and investigation of the role of the IP3 receptor in Ca2+ release in pulmonary and 
mesenteric arteries.
4. Investigation of phosphorylated myosin light chain in pulmonary vascular smooth 
muscle in CH rats, using western Blot technique.
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Ang II angiotensin II
ATP adenosine 5’-triphosphate
ACH acetycholine
big ET-1 big endothelin-1
BQ123 cyclo(-D-Trp-D-Asp-Pro-D-V al-Leu-)
BQ788 N-cis-2,6-dimethylpiperidinocarbonyl-L-r-MeLeu-D-Trp(COOMe)-D-Nie-Ona
BSA bovine serum albumin
2+
[Ca ]i intracellular calcium concentration
cAMP 3 ’ ,5 * -adenosine monophosphate
cGMP 3’,5’-guanosine monophosphate







ETa Endothelin A receptor
ETb Endothelin B receptor
ETs Endothelins
212
ED50 Dose required evoking 50% of the maximum contraction of an agonist
EGTA ethylene glycol-bis(b-aminoethylether)-N,N,N’,N’-tetra acetic acid
G protein heterotrimeric guanine nucleotide-binding protein
GTP guanosine triphosphate
HPV hypoxic pulmonary vasoconstriction
5-HT 5 -hydroxytryptamine
IP3 inositol 1,4,5-triphosphate
L-NAME N-nitro L-argine methyl ester
L-NOARG N-nitro-L-arginine
LW Lung weight





PIP pulmonary inflation pressure
PKA protein kinase A
PKB protein kinase B




PPP pulmonary perfusion pressure
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RSS rat stomach strip
SR sarcoplasmic reticulum
VSMC vascular smooth muscle cell
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Abstract 1
ET-1 sensitizes actions of vasoconstrictor agents in rat isolated perfused lungs
Q. Yu, H. Lai, B. Woodward & K.I. Williams, Department of Pharmacology, University 
of Bath, Bath, BA2 7AY.
Previous studies have shown that endothelin-1 (ET-1) can increase the sensitivity of the 
contractile apparatus to Ca2+ in permeabilized rings of rat pulmonary artery (Evans et al., 
1999). In the present study we have investigated whether ET-1 can similarly sensitise the 
pulmonary vascular bed in perfused rat lungs, which contains fine resistance vessels.
Male Wistar rats (280-340g) were anaesthetised with pentobarbital sodium (100 mg/kg, 
I.P.) and heparinized (500 IU, I.V.). The pulmonary artery was cannulated, perfused with 
Krebs solution at 37°C, aerated by 20% O2 , 75% N2 and 5% CO2 and pulmonary 
perfusion pressure (PPP) recorded via a pressure transducer (Lai et al., 1994). Lungs were 
artificially ventilated with room air at 28 strokes/min and equilibrated for 15 min before 
adding drugs. Preliminary experiments studied the optimal ET-1 concentration (0.3-3 
nM) and infusion time (15-60 min) for sensitization. These were found to be ET-1 InM, 
the sub-threshold concentration, for 30 min (n=7). Dose-responses to phenylephrine 
(PHE) and angiotensin II (ANG II) were recorded before and after infusing ET-1 (InM) 
for 30 min. Antagonists, which did not affect basal PPP, were infused for 15 minutes 
before injection of PHE and ANG II. All data shown are mean ± s.e.mean. Data were 
analysed by unpaired Student's t-test or paired t-test and significance was accepted if P < 
0.05.
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ET-1 shifted PHE and ANG II response-curves to the left (figure 1). Responses to 10 
nmoles PHE were increased from 2.96 ± 0.25 mmHg to 3.86 ± 0.45 mmHg (p<0.05, 
n=12). Responses to 10 pmoles ANG II were increased from 0.99 ±0.17 mmHg to
i— Control 
—  ET-1 (InM)
n -  12 
* P <  0.05 
* * P < 0 . 0 1
cn
'T '  3
Q 01 Q1 1 10 100
Phenylephrine (nmoles)
Figure 1: Effect of ET-1 (InM) on PHE responses in rat isolated perfused lungs.
2.57 ± 0.42 mmHg (n=8, p<0.05). Time-matched studies showed that PHE responses 
repeated after 30 min were not significantly different to controls. The selective ETa 
receptor antagonist, PD156707 (5pM) and the selective ETb receptor antagonist, BQ788 
(5pM) reversed the potentiated responses to PHE and ANG II by ET-1. PPP responses to 
10 nmoles PHE and 10 pmoles ANG II with ET-1 were reduced by PD156707 (5pM) 
from 3.86 ± 0.45 mmHg to 1.91 ± 0.26mmHg (n=4-12, PO.01), and 2.57 ± 0.42 mmHg 
to 0.95 ± 0.24mmHg (n=4-8, P<0.01), respectively. BQ788 (5pM) shifted PPP responses 
to 10 nmoles PHE and 10 pmoles ANG II with ET-1 from 3.86 ± 0.45 mmHg to 2.01 ± 
0.57mmHg (n=5-12, P<0.05) and 2.57 ± 0.42 mmHg to 0.93 ± 0.33mmHg (n=5-8, 
P<0.05), respectively. These results suggest that ET-1 can sensitize the pulmonary 
resistance vessels to vasoconstrictors and this action involves both ETa and ETb
217
receptors.
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Abstract 2
Changes in pulmonary vascular reactivity during and after chronic hypoxia in rats.
Q. Yu, P.I.Mapp, B. Woodward & K.I. Williams, Department of Pharmacy and 
Pharmacology, University of Bath, Bath, BA2 7 AY.
Chronic hypoxia (CH) induces pulmonary hypertension as a result of vasoconstriction 
and pulmonary remodelling. The pulmonary vasculature in CH also becomes hyper- 
responsive to vasoconstrictors. The aim of the present study was to investigate whether 
enhanced pulmonary vascular reactivity is solely attributable to vascular smooth muscle 
proliferation.
Male Wistar rats were exposed to normoxia or hypoxia (10% 02) for 3 weeks. For 
recovery, CH rats were returned to room air and utilised 3 weeks later. Lungs were 
perfused (Lai et a l, 1994). Phenylephrine (PHE) (l-30nmoles), KC1 (25-400umoles) and 
angiotensin II (l-300pmoles) were injected into the pulmonary artery and increases in 
pulmonary perfusion pressure (PPP) recorded. Weights of the right ventricle (RV) and 
left ventricle plus septum (LV) were measured for an index of right ventricular 
hypertrophy. For histology, after fixation with formol saline (0.4%), transverse slices 
(4pm) of lung tissue were stained with haemotoxylin and eosin. Vessel diameters (range: 
37 - 815 pm) and medial wall thickness were measured using a Zeiss KS300 computer 
image programme. The percentage wall thickness was calculated from the formula: wall 
thickness (%) = 2x wall thickness x 100/ external diameter (Hislop et a l, 1976). Data
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were expressed as mean ± s.e.mean and analysed by a one-way ANOVA with Dunnett’s 
test or Student-t test.
Basal PPP increased from 6.3 ± 0.9 mmHg in control to 10.5 ±0.2 mmHg after CH 
(P<0.05, n = 5) but fell again after recovery, (6.4 ± 0.5mmHg, P>0.05, n=6). PPP 
increases to lOnmoles PHE were 2.74 ± 0.28 mmHg in control vs 15.35 ± 3.01 mmHg in 
CH (P<0.05, n=5-7). After 3 weeks recovery, PHE responses had declined (3.08 ± 0.52 
mmHg). PPP increases to 200umoles KC1 were 8.48 ± 1.20 mmHg in control vs 18.67 ± 
3.76 mmHg in CH (P<0.05, n=5) and were still elevated after recovery (14.19 ± 1.04 
mmHg). This was also true for angiotensin II (lOOpmoles), 6.83 ± 1.08 mmHg in control 
vs 17.33 ± 3.74 mmHg in CH (P<0.05, n=5-6) and 12.02 ± 1.26 mmHg after recovery. 
RV/LV ratio was increased from 0.205 ± 0.013 in control to 0.338 ± 0.010 (P<0.05) in 
CH. After recovery the ratio (0.270 ± 0.019) was still significantly elevated (P<0.05, 
n=5-6). Similarly, pulmonary arterial wall thickness was significantly increased from 
17.5 ± 1% (n=84) in age-matched control to 21.8 ± 0.9% (n=106) in CH, P < 0.01 and 
was still higher after recovery, 18.4 ± 0.7% (n=114) in age-matched control vs 25.7 ±1% 
(n=89) in the recovery group, P0.001.
In conclusion, our study shows that CH induces pulmonary hypertension, vascular re­
modelling and markedly increases pulmonary vascular reactivity. During recovery from 
hypoxia, responses to phenylephrine decline faster than those to KC1 or angiotensin II. 
This suggests that in CH proliferation of vascular smooth muscle alone cannot account 
for the observed vascular hyper-reactivity to ai-adrenoceptor agonists.
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